


PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : G01N 33/50, 33/68, A61K 31/00, C07C 279/26	A1	(11) International Publication Number: WO 00/19200 (43) International Publication Date: 6 April 2000 (06.04.00)
(21) International Application Number: PCT/US99/22261 (22) International Filing Date: 24 September 1999 (24.09.99) (30) Priority Data: 09/161,172 25 September 1998 (25.09.98) US (71) Applicant (for all designated States except US): MITOKOR [US/US]; 11494 Sorrento Valley Road, San Diego, CA 92121 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DYKENS, James, A. [US/US]; 2117 Pleasant Grove Road, Encinitas, CA 92024 (US). MILLER, Scott, W. [US/US]; 1205 Calle Fantasia, San Marcos, CA 92069 (US). GHOSH, Soumitra, S. [US/US]; 12334 Pathos Lane, San Diego, CA 92129 (US). DAVIS, Robert, E. [US/US]; 13272 Glencliff Way, San Diego, CA 92130 (US). (74) Agents: ROSENMAN, Stephen, J. et al.; Seed and Berry LLP, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, EE, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: IDENTIFYING AGENTS THAT ALTER MITOCHONDRIAL PERMEABILITY TRANSITION PORES (57) Abstract <p>The invention is directed to methods for identifying agents that affect mitochondrial functions and cell death. Such agents are useful for treating diseases associated with mitochondrial dysfunction and to methods of identifying a risk or presence of such diseases. In particular, the invention relates to the loss of mitochondrial membrane potential ($\Delta\Psi_m$) during mitochondrial permeability transition (MPT) and further provides a measurable rate loss function, changes in which are useful, <i>inter alia</i>, for detecting agents that affect one or more mitochondrial functions, for detecting mitochondrial diseases and for studying molecular components of mitochondria that regulate MPT.</p> 		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

IDENTIFYING AGENTS THAT ALTER MITOCHONDRIAL PERMEABILITY TRANSITION PORES

TECHNICAL FIELD

The invention relates to respiratory and metabolic diseases, and in particular to diseases associated with alterations in mitochondrial function.

BACKGROUND OF THE INVENTION

Mitochondria are the main energy source in cells of higher organisms, and these organelles provide direct and indirect biochemical regulation of a wide array of cellular respiratory, oxidative and metabolic processes. These include electron transport chain (ETC) activity, which drives oxidative phosphorylation to produce metabolic energy in the form of adenosine triphosphate (ATP), and which also underlies a central mitochondrial role in intracellular calcium homeostasis.

Mitochondrial ultrastructural characterization reveals the presence of an outer mitochondrial membrane that serves as an interface between the organelle and the cytosol, a highly folded inner mitochondrial membrane that appears to form attachments to the outer membrane at multiple sites, and an intermembrane space between the two mitochondrial membranes. The subcompartment within the inner mitochondrial membrane is commonly referred to as the mitochondrial matrix. (For a review, *see, e.g.,* Ernster et al., 1981 *J. Cell Biol.* 91:227s.) The cristae, originally postulated to occur as infoldings of the inner mitochondrial membrane, have recently been characterized using three-dimensional electron tomography as also including tube-like conduits that may form networks, and that can be connected to the inner membrane by open, circular (30 nm diameter) junctions (Perkins et al., 1997, *Journal of Structural Biology* 119:260). While the outer membrane is freely permeable to ionic and non-ionic solutes having molecular weights less than about ten kilodaltons, the inner mitochondrial membrane exhibits selective and regulated permeability for many small molecules, including certain cations, and is impermeable to large (> ~10 kDa) molecules.

Altered or defective mitochondrial activity, including but not limited to failure at any step of the ETC, may result in catastrophic mitochondrial collapse that has been termed "permeability transition" (PT) or "mitochondrial permeability transition" (MPT). According to generally accepted theories of mitochondrial function, proper

5 ETC respiratory activity requires maintenance of an electrochemical potential ($\Delta\Psi_m$) in the inner mitochondrial membrane by a coupled chemiosmotic mechanism. Altered or defective mitochondrial activity may dissipate this membrane potential, thereby preventing ATP biosynthesis and halting the production of a vital biochemical energy source. In addition, mitochondrial proteins such as cytochrome c may be excreted by or

10 leak out of the mitochondria after permeability transition and may induce the genetically programmed cell suicide sequence known as apoptosis or programmed cell death (PCD).

MPT may result from direct or indirect effects of mitochondrial genes, gene products or related downstream mediator molecules and/or extramitochondrial

15 genes, gene products or related downstream mediators, or from other known or unknown causes. Loss of mitochondrial potential therefore may be a critical event in the progression of diseases associated with altered mitochondrial function, including degenerative diseases.

Mitochondrial defects, which may include defects related to the discrete

20 mitochondrial genome that resides in mitochondrial DNA and/or to the extramitochondrial genome, which includes nuclear chromosomal DNA and other extramitochondrial DNA, may contribute significantly to the pathogenesis of diseases associated with altered mitochondrial function. For example, alterations in the structural and/or functional properties of mitochondrial components comprised of

25 subunits encoded directly or indirectly by mitochondrial and/or extramitochondrial DNA, including alterations deriving from genetic and/or environmental factors or alterations derived from cellular compensatory mechanisms, may play a role in the pathogenesis of any disease associated with altered mitochondrial function. A number of degenerative diseases are thought to be caused by, or to be associated with,

30 alterations in mitochondrial function. These include Alzheimer's Disease (AD);

diabetes mellitus; Parkinson's Disease; Huntington's disease; dystonia; Leber's hereditary optic neuropathy; schizophrenia; mitochondrial encephalopathy, lactic acidosis, and stroke (MELAS); cancer; psoriasis; hyperproliferative disorders; mitochondrial diabetes and deafness (MIDD) and myoclonic epilepsy ragged red fiber
5 syndrome. The extensive list of additional diseases associated with altered mitochondrial function continues to expand as aberrant mitochondrial or mitonuclear activities are implicated in particular disease processes.

A hallmark of diseases associated with altered mitochondrial function is the death of selected cellular populations in particular affected tissues, which may result
10 from apoptosis (also referred to as "programmed cell death" or PCD) according to a growing body of evidence. Mitochondrial dysfunction is thought to be critical in the cascade of events leading to apoptosis in various cell types (Kroemer et al., *FASEB J.* 9:1277-87, 1995), and may be a cause of apoptotic cell death in neurons of the AD brain. Altered mitochondrial physiology may be among the earliest events in PCD
15 (Zamzami et al., *J. Exp. Med.* 182:367-77, 1995; Zamzami et al., *J. Exp. Med.* 181:1661-72, 1995) and elevated reactive oxygen species (ROS) levels that result from such altered mitochondrial function may initiate the apoptotic cascade (Ausserer et al., *Mol. Cell. Biol.* 14:5032-42, 1994).

Thus, in addition to their role in energy production in growing cells,
20 mitochondria (or, at least, mitochondrial components) participate in apoptosis (Newmeyer et al., 1994, *Cell* 79:353-364; Liu et al., 1996, *Cell* 86:147-157). Apoptosis is apparently also required for, *inter alia*, normal development of the nervous system and proper functioning of the immune system. Moreover, some disease states are thought to be associated with either insufficient (e.g., cancer, autoimmune diseases) or
25 excessive (e.g., stroke damage, AD-associated neurodegeneration) levels of apoptosis or cell death. For general reviews of apoptosis, and the role of mitochondria therein, see Green and Reed (1998, *Science* 281:1309-1312), Green (1998, *Cell* 94:695-698) and Kromer (1997, *Nature Medicine* 3:614-620). Hence, agents that effect apoptotic events, including those associated with mitochondrial components, might have a variety of
30 palliative, prophylactic and therapeutic uses.

When stressed, mitochondria may release pre-formed soluble factors that can induce a cascade of events leading ultimately to chromosomal condensation, an event preceding apoptosis (Marchetti et al., *Cancer Res.* 56:2033-38, 1996). In addition, members of the Bcl-2/ Bax family of apoptosis-related gene products are
5 located within the outer mitochondrial membrane (Monaghan et al., *J. Histochem. Cytochem.* 40:1819-25, 1992) and, depending on specific conditions, these proteins appear to protect against or accelerate cell death induced by various stimuli (Korsmeyer et al., *Biochim. Biophys. Act.* 1271:63, 1995). Localization of Bcl-2 to this membrane appears to be indispensable for modulation of apoptosis (Nguyen et al., *J. Biol. Chem.*
10 269:16521-24, 1994). Thus, changes in mitochondrial physiology may be important mediators of apoptosis.

Clearly there is a need for compounds and methods that limit or prevent damage to organelles, cells and tissues that may directly or indirectly result from alterations in mitochondrial function that lead to mitochondrial permeability transition.
15 In particular, because mitochondria are essential organelles for a variety of cellular activities including metabolic energy production, aerobic respiration, oxidative buffering and intracellular calcium regulation, agents (for example, mitochondria protecting agents) and methods that regulate MPT would be especially useful. Such agents and methods may be suitable for the treatment of diseases associated with altered
20 mitochondrial function, including degenerative diseases described above. Existing approaches to the identification of agents useful for such diseases do not include determination of whether such agents alter mitochondrial permeability transition pores or influence mitochondrial structure and/or function. The present invention fulfills these needs and provides other related advantages.

25 SUMMARY OF THE INVENTION

The present invention is directed to compositions and methods for treating diseases associated with altered mitochondrial function. More specifically, without wishing to be bound by any theory, according to the present disclosure it may be appreciated, *inter alia*, that the selective permeability of the inner mitochondrial

membrane may depend on the maintenance of membrane potential ($\Delta\Psi_m$), that partial or complete loss of $\Delta\Psi_m$ in mitochondrial permeability transition (MPT) may accompany loss of the selective permeability properties of the mitochondrial membrane, that MPT may be quantified as a rate loss function, that the loss of mitochondrial selective permeability may be mediated by a mitochondrial "pore" comprising one or more molecular components that regulate or otherwise affect MPT, that MPT and/or loss of $\Delta\Psi_m$ may be indicative of mitochondrial dysfunction and are present in a wide range of diseases associated with altered mitochondrial function, and that sequelae of MPT and loss of $\Delta\Psi_m$ may include induction of apoptotic pathways.

10 These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain aspects of this invention, and are therefore incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

15 Figure 1 shows fluorescent labeling of mitochondria with DASPMI in mixed control (MixCon) cybrid SH-SY5Y cells (Figure 1A) and loss of DASPMI fluorescence following ionomycin induced MPT (Figure 1B).

 Figure 2 shows measurement of ionomycin induced MPT with DASPMI as a rate loss function in SH-SY5Y cybrid cells and the effect of cyclosporin on
20 DASPMI loss rate.

 Figure 3 shows measurement of ionomycin induced MPT with DASPMI as a rate loss function in SH-SY5Y cybrid cells and the effect of ruthenium red on DASPMI loss rate.

 Figure 4 shows measurement of atractyloside induced MPT with
25 DASPMI as a rate loss function in control and AD cybrid SH-SY5Y neuroblastoma cells.

 Figure 5 shows measurement of annexin binding to control and AD SH-SY5Y cybrid cells following atractyloside induced MPT.

Figure 6 shows measurement of caspase-3 activation in control and AD SH-SY5Y cybrid cells following atractyloside induced MPT.

Figure 7 shows quantification of caspase-3 activation following ionomycin induced MPT in control and AD cybrid SH-SY5Y neuroblastoma cells.

5 Figure 8 depicts quantification of cytochrome c release from mitochondria following ionomycin induced MPT in control and AD cybrid SH-SY5Y neuroblastoma cells.

Figure 9 shows effect of pre-treating control and AD cybrid SH-SY5Y neuroblastoma cells with compound (I) on DASPMI loss rate following ionomycin
10 induced MPT.

Figure 10 shows morphology of mixed control (MixCon) cybrid SH-SY5Y neuroblastoma cells before ionomycin induced MPT (Figure 10A), four hours after ionomycin induced MPT (Figure 10B), and the effect of pre-treatment with compound (I) on cell morphology four hours after ionomycin induced MPT
15 (Figure 10C).

Figure 11 depicts the effect of pre-treating control and AD cybrid SH-SY5Y neuroblastoma cells with compound (I) on caspase-3 activation following ionomycin induced MPT.

SYMBOLS AND ABBREVIATIONS

20	$\Delta\Psi_m$	mitochondrial membrane potential
	ρ^0	essentially completely depleted of mtDNA
	AD	Alzheimer's Disease
	AMC	7-amino-4-methylcoumarin
	ANOVA	analysis of variance
25	ANT	adenine translocator
	APOE	apolipoprotein E
	DASPMI	2,4-dimethylaminostyryl-N-methylpyridinium
	DMF	dimethylformamide
	EAM	energy absorption molecule
30	ETC	electron transport chain

	FITC	fluorescein isothiocyanate
	FCCP	carbonyl cyanide p-trifluoro-methoxyphenylhydrazone
	HBSS	Hank's balanced salt solution
	JC-1	5,5',6,6'-Tetrachloro-1,1',3,3'-Tetraethylbenzimidazolcarbocyanine
5		Iodide
	MELAS	Mitochondrial Encephalopathy, Lactic Acidosis and Stroke
	MERRF	Myoclonic Epilepsy Ragged Red Fiber Syndrome
	MixCon	mixed control
	MPT	Mitochondrial Permeability Transition
10	mtDNA	mitochondrial DNA
	NMDA	N-methyl-D-aspartic acid
	PBG	1-phenylbiguanide
	PCD	Programmed Cell Death
	PMSF	phenylmethylsulfonate
15	PS	phosphatidylserine
	PT	Permeability Transition
	RFU	relative fluorescence unit(s)
	ROS	reactive oxygen species
	TMRE	tetramethylrhodamine ethyl ester
20	TMRM	tetramethylrhodamine methyl ester
	VDAC	voltage dependent anion channel

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates in part to the unexpected finding that mitochondrial permeability transition (MPT) can be monitored as a rate loss function

25 for modeling diseases associated with altered mitochondrial function. Such MPT may be manifest as a more or less continual state of some or all of a diseased organism's mitochondria, or may be temporally or spatially organized. For example, such MPT can be acute, chronic, intermittent, transient, tissue-specific, cell type-specific, mitochondrion-specific or progressively altered over time with regard to one or more of

such characteristics; MPT may also be manifest globally across all mitochondria within a cell.

The invention pertains to the dependence of the selective permeability of the inner mitochondrial membrane on the maintenance along this membrane of an electrochemical potential which, as noted above, relies upon proper functioning of the ETC. By way of background, four of the five multisubunit protein complexes (Complexes I, III, IV and V) that mediate ETC activity are localized to the inner mitochondrial membrane, which is the most protein rich of biological membranes in cells (75% by weight); the remaining ETC complex (Complex II) is situated in the matrix. In at least three distinct chemical reactions known to take place within the ETC, positively-charged protons are moved from the mitochondrial matrix, across the inner membrane, to the intermembrane space. This disequilibrium of charged species creates an electrochemical potential of approximately 220 mV referred to as the "protonmotive force" (PMF), which is often represented by the notation $\Delta\psi$ or $\Delta\psi_m$ and represents the sum of the electric potential and the pH differential across the inner mitochondrial membrane (*see, e.g., Ernster et al., 1981 J. Cell Biol. 91:227s and references cited therein*).

This membrane potential provides the energy contributed to the phosphate bond created when adenosine diphosphate (ADP) is phosphorylated to yield ATP by ETC Complex V, a process that is "coupled" stoichiometrically with transport of a proton into the matrix; $\Delta\psi_m$ is also the driving force for the influx of cytosolic Ca^{2+} into the mitochondrion. Under normal metabolic conditions, the inner membrane is impermeable to proton movement from the intermembrane space into the matrix, leaving ETC Complex V as the sole means whereby protons can return to the matrix. When, however, the integrity of the inner mitochondrial membrane is compromised, as occurs during MPT that may accompany a disease associated with altered mitochondrial function, protons are able to bypass Complex V without generating ATP, thereby "uncoupling" respiration from ATP generation. Thus, mitochondrial permeability transition involves the opening of a mitochondrial membrane "pore", a process by which, *inter alia*, the ETC is uncoupled, $\Delta\psi_m$ collapses and mitochondrial membranes

lose the ability to selectively regulate permeability to solutes both small (*e.g.*, ionic Ca^{2+} , Na^+ , K^+ , H^+) and large (*e.g.*, proteins).

Without wishing to be bound by theory, it is unresolved whether this pore is a physically discrete conduit that is formed in mitochondrial membranes, for example by assembly or aggregation of particular mitochondrial and/or cytosolic proteins and possibly other molecular species, or whether the opening of the "pore" may simply represent a general increase in the porosity of the mitochondrial membrane. In any event, because permeability transition may be potentiated by mitochondrial dysfunction, MPT may be more likely to occur in the mitochondria of cells from patients having diseases associated with altered mitochondrial function.

According to the present invention, useful embodiments may be practiced using mitochondria that exhibit no sign of altered mitochondrial function or any functional defect, preferably under conditions where MPT and/or altered ETC activity may be induced in such mitochondria, for example by artificial means described herein. In certain other preferred embodiments of the invention, it may be desirable to use functionally altered mitochondria or functionally defective mitochondria and to compare the extent of MPT in such mitochondria with that of normally functioning mitochondria, or to compare the extent of MPT in such mitochondria in the presence and absence of an agent that is known or suspected to affect MPT and/or ETC activity, and associated events such as, *e.g.*, cell death. In other preferred embodiments of the invention, the extent of MPT in mitochondria from one cell type or species is compared to the extent of MPT in mitochondria from a second cell type or species in order to screen agents that affect MPT selectively, *i.e.*, in one cell type or species but not the other.

Surprisingly, as provided by the present invention and described below, cells or mitochondria from subjects having a disease associated with altered mitochondrial function, or cybrid cells having mitochondria that exhibit altered function, appear to be more susceptible to stimuli that induce MPT than are cells or mitochondria that exhibit normal function. Thus, according to certain embodiments of the invention, MPT may be monitored in cells or mitochondria from a subject suspected

of having a disease associated with altered mitochondrial function, or cybrid cells constructed with mitochondria from such a subject, any of which may be predisposed to MPT by the criteria of altered mitochondrial function, including but not limited to: elevated free radicals, impaired ETC and/or respiratory enzyme activity or disrupted
5 intracellular calcium homeostasis. However, other subcellular events that take place in cells of individuals having diseases associated with altered mitochondrial function, regardless of whether or not free radical reactivity or elevated cytosolic calcium are involved, may also potentiate MPT and should be considered within the scope of the invention. The invention may be practiced with any disease or condition having MPT
10 as a diagnostic, prognostic or clinical parameter.

Typically, mitochondrial membrane potential may be determined according to methods with which those skilled in the art will be readily familiar, including but not limited to detection and/or measurement of detectable compounds such as fluorescent indicators, optical probes and/or sensitive pH and ion-selective
15 electrodes (*See, e.g.,* Ernster et al., 1981 *J. Cell Biol.* 91:227s and references cited; *see also* Haugland, 1996 *Handbook of Fluorescent Probes and Research Chemicals- Sixth Ed.*, Molecular Probes, Eugene, OR, pp. 266-274 and 589-594.). For example, by way of illustration and not limitation, the fluorescent probes 2-,4-dimethylaminostyryl-N-methyl pyridinium (DASPMI) and tetramethylrhodamine esters (such as, *e.g.,*
20 tetramethylrhodamine methyl ester, TMRM; tetramethylrhodamine ethyl ester, TMRE) or related compounds (*see, e.g.,* Haugland, 1996, *supra*) may be quantified following accumulation in mitochondria, a process that is dependent on, and proportional to, mitochondrial membrane potential (*see, e.g.,* Murphy et al., 1998 in *Mitochondria & Free Radicals in Neurodegenerative Diseases*, Beal, Howell and Bodis-Wollner, Eds.,
25 Wiley-Liss, New York, pp. 159-186 and references cited therein; and *Molecular Probes On-line Handbook of Fluorescent Probes and Research Chemicals*, at <http://www.probes.com/handbook/toc.html>). Other fluorescent detectable compounds that may be used in the invention include but are not limited to rhodamine 123, rhodamine B hexyl ester, DiOC₆(3), JC-1 [5,5',6,6'-Tetrachloro-1,1',3,3'-
30 Tetracthylbezimidazolcarbocyanine Iodide] (*see* Cossarizza, et al., 1993 *Biochem.*

Biophys. Res. Comm. 197:40; Reers et al., 1995 *Meth. Enzymol.* 260:406), rhod-2 (see U.S. Patent No. 5,049,673; all of the preceding compounds are available from Molecular Probes, Eugene, Oregon) and rhodamine 800 (Lambda Physik, GmbH, Göttingen, Germany; see Sakanoue et al., 1997 *J. Biochem.* 121:29).

5 Mitochondrial membrane potential can also be measured by non-fluorescent means, for example by using TTP (tetraphenylphosphonium ion) and a TTP-sensitive electrode (Kamo et al., 1979 *J. Membrane Biol.* 49:105; Porter and Brand, 1995 *Am. J. Physiol.* 269:R1213). Those skilled in the art will be able to select appropriate detectable compounds or other appropriate means for measuring $\Delta\Psi_m$.
10 By way of example and not limitation, TMRM is somewhat preferable to TMRE because, following efflux from mitochondria, TMRE yields slightly more residual signal in the endoplasmic reticulum and cytoplasm than TMRM.

As another non-limiting example, membrane potential may be additionally or alternatively calculated from indirect measurements of mitochondrial
15 permeability to detectable charged solutes, using matrix volume and/or pyridine nucleotide redox determination combined with spectrophotometric or fluorimetric quantification. Measurement of membrane potential dependent substrate exchange-diffusion across the inner mitochondrial membrane may also provide an indirect measurement of membrane potential. (See, e.g., Quinn, 1976, *The Molecular Biology of*
20 *Cell Membranes*, University Park Press, Baltimore, Maryland, pp. 200-217 and references cited therein.)

Thus, as provided herein, any experimentally measurable consequence for cells containing mitochondria undergoing MPT may be used, including, for example, measurement of the dissipation of $\Delta\Psi$, detection of the loss of mitochondrial
25 intermembrane space proteins such as cytochrome c to the cytoplasm, activation of caspase 3 as a downstream event in the apoptotic signaling cascade (see below), cell death and any other phenotypic, biochemical, biophysical, metabolic, respiratory or other useful parameter the alteration of which may depend on MPT. Agents (including mitochondria protecting agents) identified according to the methods of the present
30 invention that are suitable for treatment of a disease associated with altered

mitochondrial function may potentiate, impair or alter the frequency and/or occurrence of MPT and/or MPT-related regulatory mechanisms. Particularly preferred are agents that inhibit the appearance of one or more of the above indicators of MPT.

Certain aspects of the present invention as it relates to modeling diseases
5 associated with altered mitochondrial function, involve the relationship between $\Delta\Psi$ and intracellular calcium homeostasis. Normal alterations of intramitochondrial Ca^{2+} are associated with normal metabolic regulation (Dyken, 1998 in *Mitochondria & Free Radicals in Neurodegenerative Diseases*, Beal, Howell and Bodis-Wollner, Eds., Wiley-Liss, New York, pp. 29-55; Radi et al., 1998 in *Mitochondria & Free Radicals in*
10 *Neurodegenerative Diseases*, Beal, Howell and Bodis-Wollner, Eds., Wiley-Liss, New York, pp. 57-89; Gunter and Pfeiffer, 1991, *Am. J. Physiol.* 27: C755; Gunter et al., 1994, *Am. J. Physiol.* 267: 313). For example, fluctuating levels of mitochondrial free Ca^{2+} may be responsible for regulating oxidative metabolism in response to increased ATP utilization, via allosteric regulation of enzymes (reviewed by Crompton and
15 Andreeva, 1993 *Basic Res. Cardiol.* 88: 513-523;) and the glycerophosphate shuttle (Gunter and Gunter, 1994 *J. Bioenerg. Biomembr.* 26: 471).

Normal mitochondrial function includes regulation of cytosolic free calcium levels by sequestration of excess Ca^{2+} within the mitochondrial matrix. Depending on cell type, cytosolic Ca^{2+} concentration is typically 50-100 nM. In
20 normally functioning cells, when Ca^{2+} levels reach 200-300 nM, mitochondria begin to accumulate Ca^{2+} as a function of the equilibrium between influx via a Ca^{2+} uniporter in the inner mitochondrial membrane and Ca^{2+} efflux via both Na^{+} dependent and Na^{+} -independent calcium carriers. The low affinity of this rapid uniporter mechanism suggests that the primary uniporter function may be to lower cytosolic Ca^{2+} in response
25 to pathological elevation of cytosolic free calcium levels, which may result from ATP depletion and/or abnormal calcium influx across the plasma membrane (Gunter and Gunter, 1994 *J. Bioenerg. Biomembr.* 26: 471; Gunter et al., 1994 *Am. J. Physiol.* 267:313). In certain instances, such perturbation of intracellular calcium homeostasis is a feature of diseases associated with altered mitochondrial function, regardless of

whether the calcium regulatory dysfunction is causative of, or a consequence of, altered mitochondrial function including MPT.

Mitochondrial calcium levels may also reflect transient low cytosolic concentrations, which, in combination with reduced ATP or other conditions associated with mitochondrial pathology can yield MPT (see Gunter et al., 1998 *Biochim. Biophys. Acta* 1366:5; Rottenberg and Marbach, 1990, *Biochim. Biophys. Acta* 1016:87). Generally, in order to practice the present invention on a given set of mitochondria, the extramitochondrial (cytosolic) level of Ca^{2+} is greater than that present within mitochondria. In the case of diseases or disorders, including diseases associated with altered mitochondrial function, mitochondrial or cytosolic calcium levels may vary from the above ranges and may range from, e.g., about 1 nM to about 500 mM, more typically from about 10 nM to about 100 μM and usually from about 20 nM to about 1 μM , where "about" indicates $\pm 10\%$. A variety of calcium indicators are known in the art including but not limited to fura-2 (McCormack et al., 1989 *Biochim. Biophys. Acta* 973:420); mag-fura-2; BTC (U.S. Patent No. 5,501,980); fluo-3, fluo-4 and fluo-5N (U.S. Patent No. 5,049,673); benzothiaz-1; and benzothiaz-2 (all of which are available from Molecular Probes, Eugene, OR).

Ca^{2+} influx into mitochondria appears to be largely dependent, and may be completely dependent, upon the negative transmembrane electrochemical potential ($\Delta\Psi$) established by electron transfer, and such influx fails to occur in the absence of $\Delta\Psi$ even when an eight-fold Ca^{2+} concentration gradient is imposed (Kapus et al., 1991 *FEBS Lett.* 282:61). Accordingly, mitochondria may release Ca^{2+} via the uniporter when the membrane potential is dissipated, as occurs with uncouplers like 2,4-dinitrophenol and carbonyl cyanide p-trifluoro-methoxyphenylhydrazone (FCCP).

Thus, according to certain embodiments of the present invention, MPT may be potentiated by influxes of cytosolic free calcium into the mitochondria, as may occur under certain physiological conditions including those encountered by cells of a subject having a disease associated with altered mitochondrial function. As noted above, in certain instances cells exposed to appropriate ionophores or other agents or conditions that directly or indirectly induce calcium fluxes across the plasma

membrane into the cytoplasm undergo MPT in response to excessive sequestration of Ca^{2+} in the mitochondrial matrix by mitochondrial calcium regulatory mechanisms. Additionally, a variety of physiologically pertinent agents, including hydroperoxide and free radicals, may synergize with Ca^{2+} to induce MPT (Novgorodov et al., 1991
5 *Biochem. Biophys. Acta* 1058: 242; Takeyama et al., 1993 *Biochem. J.* 294: 719; Guidox et al., 1993 *Arch. Biochem. Biophys.* 306:139).

Compounds that induce increased cytoplasmic and mitochondrial concentrations of Ca^{2+} , including calcium ionophores, are well known to those of ordinary skill in the art, as are methods for measuring intracellular calcium and
10 intramitochondrial calcium (see, e.g., Gunter and Gunter, 1994 *J. Bioenerg. Biomembr.* 26: 471; Gunter et al., 1998 *Biochim. Biophys. Acta* 1366:5; McCormack et al., 1989 *Biochim. Biophys. Acta* 973:420; Orrenius and Nicotera, 1994 *J. Neural. Transm. Suppl.* 43:1; Leist and Nicotera, 1998 *Rev. Physiol. Biochem. Pharmacol.* 132:79; and Haugland, 1996, *supra*). Accordingly, a person skilled in the art may readily select a
15 suitable ionophore (or another compound or procedure that results in increased cytoplasmic and/or mitochondrial concentrations of Ca^{2+}) and an appropriate means for detecting intracellular and/or intramitochondrial calcium for use in the present invention, according to the instant disclosure and to well known methods. In addition to ionophores, other compounds that induce increased cytoplasmic and mitochondrial
20 concentrations of Ca^{2+} include but are not limited to thapsigargin, carbachol and amino acid neurotransmitters such as glutamate or N-methyl-D-aspartic acid. As will be appreciated by those familiar with the art, the particular cells that are exposed to a given compound such as glutamate require a receptor therefor, in order for the compound to influence intracellular Ca^{2+} levels. For example, NT-2 teratocarcinoma cells express
25 such glutamate receptors, whereas SH-5YSY neuroblastoma cells do not. Thus, the choice of cell line in which it may be desirable to increase cytoplasmic and mitochondrial calcium levels will determine which compounds are most appropriate.

For example, by way of illustration and not limitation, in certain preferred embodiments of the invention, ionomycin (Toeplitz et al., 1979 *J. Amer.*
30 *Chem. Soc.* 101:3344) may be used as a calcium ionophore and DASPMI (Haugland,

1996 *Handbook of Fluorescent Probes and Research Chemicals- Sixth Ed.*, Molecular Probes, Eugene, Oregon, pp. 266-274) may be a fluorescent indicator of mitochondrial calcium content. In general, any appropriate compound that results in increased cytoplasmic and/or mitochondrial concentrations of Ca^{2+} and any indicator of
5 mitochondrial membrane potential that permits measuring mitochondrial permeability transition in a biological sample may be used to practice the invention. It is known in the art how to determine suitable concentrations of any such compounds for the uses contemplated herein (see, e.g., Takei and Endo, 1994 *Brain Res.* 652:65; Hatanaka et al., 1996 *Biochem. Biophys. Res. Commun.* 227:513).

10 Because loss of membrane potential causes mitochondria to release Ca^{2+} into the cytosol, the Ca^{2+} load on nearby mitochondria is increased, setting up a chain reaction (Darley-Usmar et al., 1991 *Ann. Med.* 23:583). Independent of the pathological sequelae of PT collapse, which include increased radical production from uncoupled electron transfer, the ensuing loss of ATP *per se* may be lethal to aerobically
15 poised cells (Jurkowitz-Alexander et al., 1992 *J. Neurochem.* 59:344). In addition to a reduced metabolic energy supply, the lack of ATP may exacerbate $\Delta\Psi_m$ collapse. Conversely, adding exogenous ATP (but not ADP or AMP) to cells may prevent MPT even when cytosolic Ca^{2+} is present at concentrations that would be sufficient to elicit pore opening in the absence of ATP (Duchen, et al., 1993, *Cardiovasc. Res.* 27: 1790).

20 MPT may also be induced by compounds that bind one or more mitochondrial molecular components. Such compounds include, but are not limited to, atractyloside and bongkreikic acid. Methods of determining appropriate amounts of such compounds to induce MPT are known in the art (see, e.g., Beutner et al., 1998 *Biochim. Biophys. Acta* 1368:7; Obatomi and Bach, 1996 *Toxicol. Lett.* 89:155; Green
25 and Reed, 1998 *Science* 281:1309; Kroemer et al., 1998 *Annu. Rev. Physiol.* 60:619; and references cited therein).

In certain aspects of the invention, an altered mitochondrial state is induced by exposing a biological sample to compositions known as "apoptogens," agents that induce programmed cell death (PCD or "apoptosis"). For reviews of
30 apoptosis, see Green et al. (*Science* 281:1309-1312, 1998), Raff (*Nature* 396:119-122,

1998), and Susin et al. (*Biochim. et. Biophys. Acta* 1366:151-165, 1998). A variety of apoptogens are known to those familiar with the art and may include by way of illustration herbimycin A (Mancini et al., 1997 *J. Cell. Biol.* 138:449-469); paraquat (Costantini et al., 1995 *Toxicology* 99:1-2); ethylene glycols (<http://www.ulaval.ca/vrr/rech/Proj/532866.html>); protein kinase inhibitors such as, e.g.: staurosporine, calphostin C, caffeic acid phenethyl ester, chelerythrine chloride, genistein, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine, N-[2-((p-bromocinnamyl)amino)ethyl]-5-5-isoquinolinesulfonamide, KN-93, quercitin and d-erythro-sphingosine derivatives; ultraviolet radiation; ionophores such as, e.g., ionomycin, valinomycin and other ionophores known in the art; MAP kinase inducers such as, e.g., anisomycin and anandamine; cell cycle blockers such as, e.g. aphidicolin, colcemid, 5-fluorouracil and homoharringtonine; acetylcholinesterase inhibitors such as, e.g., berberine; anti-estrogens such as, e.g., tamoxifen; pro-oxidants such as, e.g., tert-butyl peroxide and hydrogen peroxide; free radicals such as, e.g., nitrous oxide; inorganic metal ions, such as, e.g., cadmium; gangliosides, e.g., GD₃; DNA synthesis inhibitors such as, e.g., actinomycin D, bleomycin sulfate, hydroxyurea, methotrexate, mitomycin C, camptothecin, daunorubicin and DNA intercalators such as, e.g., doxorubicin; protein synthesis inhibitors such as, e.g., cycloheximide, puromycin, and rapamycin; agents that effect microtubule formation or stability such as, e.g.: vinblastine, vincristine, colchicine, 4-hydroxyphenylretinamide and paclitaxel; agents that may be contacted with cells having appropriate receptors including, by way of example and not limitation, tumor necrosis factor (TNF), FasL, glutamate, NMDA, (the preceding are contacted with cells having receptors that mediate the uptake of the indicated agent), corticosterone (for use with cells having one or more mineralcorticoid or glucocorticoid receptors); agents that are withdrawn from the culture media of cells after some period of time such as, by way of non-limiting example, the withdrawal of IL-2 from lymphocytes; and agents that can be contacted with isolated mitochondria or permeabilized cells including, by way of example and not limitation, calcium and inorganic phosphate. (Kroemer et al., *Ann. Rev. Physiol.* 60:619-642, 1998) and members of the Bax/Bcl-2 family of proteins (Jurgenmeier et al., *Proc. Natl. Acad. Sci.*

U.S.A. 95:4997-5002, 1998). Such agents are prepared according to methods known in the art or are commercially available from companies such as, for example, Calbiochem (San Diego, CA) and Sigma Chemical Company (St. Louis, MO). Apoptogens and MPT inducers are added to appropriate biological samples comprising mitochondria, under appropriate conditions with which those skilled in the art will be familiar.

In certain aspects of the invention, an altered mitochondrial state is induced by exposing a biological sample comprising mitochondria to one or more agents or conditions that affect mitochondrial permeability transition but which may or may not induce apoptosis at a given concentration, under a particular set of conditions and/or in a specific cell line. Such agents and conditions include voltage; matrix pH; surface potential; divalent cations such as Ca^{++} , Sr^{++} , Mn^{++} and Mg^{++} ; agents that specifically interact with ANT, for example, cyclophilin D, atractyloside, carboxyatractyloside, bongkreic acid and isobongkreic acid; agents that affect ANT interactions with other compounds or proteins, for example, cyclosporin A and its nonimmunosuppressive analog N-methyl-Val-4-cyclosporin A (PKF 220-384); dithiols; glutathione; pyridine nucleotides; quinones (see Bernardi et al., *Eur. J. Biochem.* 264:687-701, 1999, and references cited therein); chloromethyltetramethylrosamine (MitoTracker Orange™; Scorrano et al., *J. Biol. Chem.* 274:24657-24663, 1999); *t*-butylhydroperoxide or phenylarsine oxide (Petronilli et al., *Biophys. J.* 76:725-734, 1999); and gangliosides such as GD3 (Scorrano et al., *J. Biol. Chem.* 274:22581-22585, 1999).

Using methodologies known in the art and/or the present disclosure, those skilled in the art will be able to determine appropriate doses, conditions and samples (e.g., isolated mitochondria, whole or permeabilized cells, and appropriate cell types or lines) for assays utilizing specific agents and/or conditions for inducing an altered mitochondrial state. Cells may be permeabilized by the addition of permeabilizing agents such as digitonin, streptolysin O, *Staphylococcus aureus* α -toxin (α -hemolysin), saponin (all available from Sigma Chemical Co., St. Louis, MO; see Sigma catalog entitled "Biochemicals and Reagents for Life Science Research," Anon.,

1999, and references cited therein for these permeabilizing agents), or by physical manipulations, for example, electroporation or other permeabilization techniques.

As described herein, isolation of a mitochondrial pore component or a mitochondrial molecular species with which an agent identified according to the methods of the invention interacts refers to physical separation of such a complex from its biological source, and may be accomplished by any of a number of well known techniques including but not limited to those described herein, and in the cited references. Without wishing to be bound by theory, a compound that “binds a mitochondrial component” can be any discrete molecule, agent compound, composition of matter or the like that may, but need not, directly bind to a mitochondrial molecular component, and may in the alternative bind indirectly to a mitochondrial molecular component by interacting with one or more additional components that bind to a mitochondrial molecular component. These or other mechanisms by which a compound may bind to and/or associate with a mitochondrial molecular component are within the scope of the claimed methods, so long as isolating a mitochondrial pore component also results in isolation of the mitochondrial molecular species that directly or indirectly binds to the identified agent.

As described herein, the mitochondrial permeability transition “pore” may not be a discrete assembly or multisubunit complex, and the term thus refers instead to any mitochondrial molecular component (including, *e.g.*, a mitochondrial membrane *per se*) that regulates the inner membrane selective permeability where such regulated function is impaired during MPT. As used herein, mitochondria are comprised of “mitochondrial molecular components”, which may be any protein, polypeptide, peptide, amino acid, or derivative thereof; any lipid, fatty acid or the like, or derivative thereof; any carbohydrate, saccharide or the like or derivative thereof, any nucleic acid, nucleotide, nucleoside, purine, pyrimidine or related molecule, or derivative thereof, or the like; or any other biological molecule that is a constituent of a mitochondrion. “Mitochondrial molecular components” includes but is not limited to “mitochondrial pore components”. A “mitochondrial pore component” is any mitochondrial molecular component that regulates the selective permeability

characteristic of mitochondrial membranes as described above, including those responsible for establishing $\Delta\Psi_m$ and those that are functionally altered during MPT.

In addition to monitoring Ca^{2+} release, other techniques may be used to follow the progression and extent of MPT and/or MPT-associated events. By way of example and not limitation, other measures of the downstream consequences of MPT include the exteriorization of plasma membrane phosphatidylserine, release of cytochrome c from mitochondria and induction of specific proteases known as caspases (Green and Reed, 1998 *Science* 281:1309). Exemplary means of monitoring these processes are described in Examples 5, 7 and 9, respectively, of the present specification.

The present invention provides methods for identifying an agent (including, for example, a mitochondria protecting agent) suitable for treatment of a subject suspected of having a disease associated with altered mitochondrial function by measuring MPT, and thus discloses assays for detecting an agent that influences the effect of any mitochondrial permeability pore component on the permeability properties of the mitochondrial inner membrane. In certain embodiments of the invention, for example, model cell based systems are established in which MPT is induced and detected, as described herein, and further wherein an agent that influences MPT is identified. Accordingly it is understood that the methods of the invention allow for the identification of agents that affect mitochondrial pore activity and may further be used in the identification of known or suspected molecular species that are components of the pore, as well as other molecular components of mitochondria that are responsible for pore properties.

Identification of an agent that affects mitochondrial pore activity according to the present invention provides an agent that may be useful in a pharmaceutical composition. The pharmaceutical composition will include at least one of a pharmaceutically acceptable carrier, diluent or excipient, in addition to one or more agent that affects mitochondrial pore activity and, optionally, other components.

"Pharmaceutically acceptable carriers" for therapeutic use are well known in the pharmaceutical art, and are described, for example, in *Remingtons*

Pharmaceutical Sciences, Mack Publishing Co. (A.R. Gennaro edit. 1985). For example, sterile saline and phosphate-buffered saline at physiological pH may be used. Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition. For example, sodium benzoate, sorbic acid and esters of
5 *p*-hydroxybenzoic acid may be added as preservatives. *Id.* at 1449. In addition, antioxidants and suspending agents may be used. *Id.*

“Pharmaceutically acceptable salt” refers to salts of the compounds of the present invention derived from the combination of such compounds and an organic or inorganic acid (acid addition salts) or an organic or inorganic base (base addition
10 salts). The compounds of the present invention may be used in either the free base or salt forms, with both forms being considered as being within the scope of the present invention.

The pharmaceutical compositions that contain one or more agent that affects mitochondrial pore activity may be in any form which allows for the
15 composition to be administered to a patient. For example, the composition may be in the form of a solid, liquid or gas (aerosol). Typical routes of administration include, without limitation, oral, topical, parenteral (*e.g.*, sublingually or buccally), intrathecal, sublingual, rectal, vaginal, and intranasal. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal, intracavernous,
20 intrameatal, intraurethral injection or infusion techniques. The pharmaceutical composition is formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will be administered to a patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of one or more
25 compounds of the invention in aerosol form may hold a plurality of dosage units.

For oral administration, an excipient and/or binder may be present. Examples are sucrose, kaolin, glycerin, starch dextrins, sodium alginate, carboxymethylcellulose and ethyl cellulose. Coloring and/or flavoring agents may be present. A coating shell may be employed.

The composition may be in the form of a liquid, *e.g.*, an elixir, syrup, solution, emulsion or suspension. The liquid may be for oral administration or for delivery by injection, as two examples. When intended for oral administration, preferred composition contain, in addition to one or more agent that affects
5 mitochondrial pore activity, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition intended to be administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.

A liquid pharmaceutical composition as used herein, whether in the form
10 of a solution, suspension or other like form, may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents
15 such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Physiological saline
20 is a preferred adjuvant. An injectable pharmaceutical composition is preferably sterile.

A liquid composition intended for either parenteral or oral administration should contain an amount of agent that affects mitochondrial pore activity such that a suitable dosage will be obtained. Typically, this amount is at least 0.01 wt % of an agent that affects mitochondrial pore activity in the composition. When intended for
25 oral administration, this amount may be varied to be between 0.1 and about 70% of the weight of the composition. Preferred oral compositions contain between about 4% and about 50% of agent(s) that affects mitochondrial pore activity. Preferred compositions and preparations are prepared so that a parenteral dosage unit contains between 0.01 to 1% by weight of active compound.

The pharmaceutical composition may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, beeswax, mineral oil, diluents
5 such as water and alcohol, and emulsifiers and stabilizers. Thickening agents may be present in a pharmaceutical composition for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device. Topical formulations may contain a concentration of the agent that affects mitochondrial pore activity compound of from about 0.1 to about 10% w/v
10 (weight per unit volume).

The composition may be intended for rectal administration, in the form, *e.g.*, of a suppository which will melt in the rectum and release the drug. The composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient. Such bases include, without limitation, lanolin, cocoa butter and
15 polyethylene glycol.

In the methods of the invention, the agent(s) that affects mitochondrial pore activity may be administered through use of insert(s), bead(s), timed-release formulation(s), patch(es) or fast-release formulation(s).

It will be evident to those of ordinary skill in the art that the optimal
20 dosage of the agent(s) that affects mitochondrial pore activity may depend on the weight and physical condition of the patient; on the severity and longevity of the physical condition being treated; on the particular form of the active ingredient, the manner of administration and the composition employed. It is to be understood that use of an agent that affects mitochondrial pore activity in a chemotherapy can involve such
25 a compound being bound to an agent, for example, a monoclonal or polyclonal antibody, a protein or a liposome, which assist the delivery of said compound.

Isolation and, optionally, identification and/or characterization of the mitochondrial pore component or components with which an agent that affects mitochondrial pore activity interacts may also be desirable and are within the scope of
30 the invention. Once an agent is shown to alter MPT according to the methods provided

herein, those having ordinary skill in the art will be familiar with a variety of approaches that may be routinely employed to isolate the molecular species specifically recognized by such an agent and involved in regulation of MPT, where to "isolate" as used herein refers to separation of such molecular species from the natural biological environment. Techniques for isolating a mitochondrial permeability transition pore component may include any biological and/or biochemical methods useful for separating the complex from its biological source, and subsequent characterization may be performed according to standard biochemical and molecular biology procedures. Those familiar with the art will be able to select an appropriate method depending on the biological starting material and other factors. Such methods may include, but need not be limited to, radiolabeling or otherwise detectably labeling cellular and mitochondrial components in a biological sample, cell fractionation, density sedimentation, differential extraction, salt precipitation, ultrafiltration, gel filtration, ion-exchange chromatography, partition chromatography, hydrophobic chromatography, electrophoresis, affinity techniques or any other suitable separation method that can be adapted for use with the agent with which the mitochondrial pore component interacts. Antibodies to partially purified components may be developed according to methods known in the art and may be used to detect and/or to isolate such components.

Affinity techniques may be particularly useful in the context of the present invention, and may include any method that exploits a specific binding interaction between a mitochondrial pore component and an agent identified according to the invention that interacts with the pore component. (See, *e.g.*, Crompton et al., 1998 *Eur. J. Biochem.* 258:729; Woodfield et al., 1998 *Biochem. J.* 336:287.) For example, because agents that influence MPT can be immobilized on solid phase matrices, an affinity binding technique for isolation of the pore component may be particularly useful. Alternatively, affinity labeling methods for biological molecules, in which a PT-active agent may be modified with a reactive moiety, are well known and can be readily adapted to the interaction between the agent and a pore component, for purposes of introducing into the pore component a detectable and/or recoverable

labeling moiety. (See, e.g., *Pierce Catalog and Handbook*, 1994 Pierce Chemical Company, Rockford, IL; Scopes, R.K., *Protein Purification: Principles and Practice*, 1987, Springer-Verlag, New York; and Hermanson, G.T. et al., *Immobilized Affinity Ligand Techniques*, 1992, Academic Press, Inc., California; for details regarding
5 techniques for isolating and characterizing biological molecules, including affinity techniques.

Characterization of mitochondrial pore component molecular species, isolated by PT-active agent affinity techniques described above or by other biochemical methods, may be accomplished using physicochemical properties of the pore
10 component such as spectrometric absorbance, molecular size and/or charge, solubility, peptide mapping, sequence analysis and the like. (See, e.g., Scopes, *supra*.) Additional separation steps for biomolecules may be optionally employed to further separate and identify molecular species that co-purify with mitochondrial pore components. These are well known in the art and may include any separation methodology for the isolation
15 of proteins, lipids, nucleic acids or carbohydrates, typically based on physicochemical properties of the newly identified components of the complex. Examples of such methods include RP-HPLC, ion exchange chromatography, hydrophobic interaction chromatography, hydroxyapatite chromatography, native and/or denaturing one- and two-dimensional electrophoresis, ultrafiltration, capillary electrophoresis, substrate
20 affinity chromatography, immunoaffinity chromatography, partition chromatography or any other useful separation method.

For example, sufficient amounts of a mitochondrial pore protein may be obtained for partial structural characterization by microsequencing. Using the sequence data so generated, any of a variety of well known suitable strategies for further
25 characterizing the pore components may be employed. For example, nucleic acid probes may be synthesized for screening one or more appropriately chosen cDNA libraries to detect, isolate and characterize a cDNA encoding such component(s). Other examples may include use of the partial sequence data in additional screening contexts that are well known in the art for obtaining additional amino acid and/or nucleotide
30 sequence information. See, e.g., *Molecular Cloning: A Laboratory Manual*, Third

Edition, edited by Sambrook, Fritsch & Maniatis, Cold Spring Harbor Laboratory, 1989. Such approaches may further include nucleic acid library screening based on expression of library sequences as polypeptides, such as binding of such polypeptides to PT-active agents identified according to the present invention; or phage display
5 screening approaches or dihybrid screening systems based on protein-protein interactions with known mitochondrial proteins, and the like, any of which may be adapted to screening for PT pore components provided by the present invention using routine methodologies with which those having ordinary skill in the art will be familiar. (See, e.g., Bartel et al., In *Cellular Interactions in Development: A Practical Approach*,
10 Ed. D.A. Harley, 1993 Oxford University Press, Oxford, United Kingdom, pp. 153-179, and references cited therein.) Preferably extracts of cultured cells, and in particularly preferred embodiments extracts of biological tissues or organs may be sources of novel mitochondrial PT pore proteins. Preferred sources may include blood, brain, fibroblasts, myoblasts, liver cells or other cell types.

15 Certain mitochondrial molecular components may contribute to the MPT mechanism, including ETC components or other mitochondrial components described herein. For example, adenine nucleotide translocator (ANT) is believed to mediate ATP/proton exchange across the inner mitochondrial membrane, and the ANT inhibitors atractyloside or bongkrekic acid may induce MPT. Three ANT isoforms
20 have been described that differ in their tissue expression patterns. (Wallace et al., 1998 in *Mitochondria & Free Radicals in Neurodegenerative Diseases*, Beal, Howell and Bodis-Wollner, Eds., Wiley-Liss, New York, pp. 283-307) Other non-limiting examples of mitochondrial or mitochondria associated proteins that appear to contribute to the MPT mechanism include members of the voltage dependent anion channel
25 (VDAC, also known as porin) family of proteins, the mitochondrial calcium uniporter, mitochondria associated hexokinase(s), peripheral benzodiazepine receptor, intermembrane creatine kinases and cyclophilin D. The PT pore may be selectively inhibited by cyclosporin A, which may block MPT by inhibiting cyclophilin D
peptidyl-prolyl isomerase activity or cyclophilin D interactions with other
30 mitochondrial proteins (Murphy et al., 1998 in *Mitochondria & Free Radicals in*

Neurodegenerative Diseases, Beal, Howell and Bodis-Wollner, Eds., Wiley-Liss, New York, pp. 159-186; White and Reynolds, 1996 *J. Neurosci.* 16:5688). The role in MPT of these and other mitochondrial molecular components, and factors influencing such components, may be investigated using the invention.

5 A biological sample containing mitochondria may comprise any tissue or cell preparation in which intact mitochondria capable of maintaining a membrane potential when supplied with one or more oxidizable substrates such as glucose, malate or galactose are or are thought to be present. By "capable of maintaining a potential" it is meant that such mitochondria have a membrane potential that is sufficient to permit
10 the accumulation of the detectable compound (*e.g.*, DASPMI, TMRM, *etc.*) used in the particular instance. A biological sample may, for example, be derived from a normal (*i.e.*, healthy) individual or from an individual having a disease associated with altered mitochondrial function. Biological samples may be provided by obtaining a blood sample, biopsy specimen, tissue explant, organ culture or any other tissue or cell
15 preparation from a subject or a biological source. The subject or biological source may be a human or non-human animal, a primary cell culture or culture adapted cell line including but not limited to genetically engineered cell lines that may contain chromosomally integrated or episomal recombinant nucleic acid sequences, immortalized or immortalizable cell lines, somatic cell hybrid or cytoplasmic hybrid
20 "cybrid" cell lines, differentiated or differentiable cell lines, transformed cell lines and the like. In particularly preferred embodiments, the subject or biological source is a cybrid cell line produced as known in the art and described herein using ρ^0 cells or mitochondrial DNA depleted cells that are repopulated with mitochondria from a human or non-human animal subject of interest. (*See, e.g.*, WO 95/26973.) In certain
25 preferred embodiments of the invention, the subject or biological source may have or be at risk for having a disease associated with altered mitochondrial function, and in certain preferred embodiments of the invention the subject or biological source may be known to be free of a risk or presence of such as disease.

 In certain other preferred embodiments where it is desirable to determine
30 whether or not a subject or biological source falls within clinical parameters indicative

of Alzheimer's disease (AD), signs and symptoms of AD that are accepted by those skilled in the art may be used to so designate a subject or biological source, for example clinical signs referred to in McKhann et al. (*Neurology* 34:939, 1984, National Institute of Neurology, Communicative Disorders and Stroke and Alzheimer's Disease and
5 Related Disorders Association Criteria of Probable AD, NINCDS-ADRDA) and references cited therein, or other means known in the art for diagnosing AD.

In certain aspects of the invention, biological samples containing mitochondria may be obtained from a subject or biological source before and after contacting the biological sample with a candidate agent, for example to identify a
10 candidate agent capable of effecting a change in mitochondrial inner membrane permeability, as defined above, relative to the mitochondrial inner membrane permeability before exposure of the subject or biological source to the agent.

In a preferred embodiment of the invention, the biological sample containing mitochondria may comprise a crude buffy coat fraction of whole blood,
15 which is known in the art to comprise further a particulate fraction of whole blood enriched in white blood cells and platelets and substantially depleted of erythrocytes. Those familiar with the art will know how to prepare such a buffy coat fraction, which may be prepared by differential density sedimentation of blood components under defined conditions, including the use of density dependent separation media, or by other
20 methods.

According to certain embodiments of the invention, the particular cell type or tissue type from which a biological sample is obtained may influence qualitative or quantitative aspects of the mitochondrial permeability measured therein relative to mitochondrial permeability in distinct cell or tissue types from a common biological
25 source. As described above, some diseases associated with altered mitochondrial function may manifest themselves in particular cell or tissue types. For example, AD is primarily a neurodegenerative disease that particularly effects changes in the central nervous system (CNS). It is therefore within the invention to quantify mitochondrial permeability in biological samples from different cell or tissue types as may render the
30 advantages of the invention most useful for a particular disease associated with altered

mitochondrial function, and the relevant cell or tissue types will be known to those familiar with such diseases.

Within the present invention, it is also useful to construct a model system for diagnostic tests and for screening candidate therapeutic agents in which the nuclear genetic background may be held constant while the mitochondrial genome is modified. It is known in the art to deplete mitochondrial DNA from cultured cells to produce ρ^0 cells, thereby preventing expression and replication of mitochondrial genes and inactivating mitochondrial function. See, for example, International PCT Publication Number WO 95/26973, which is hereby incorporated by reference in its entirety, and references cited therein.

The term " ρ^0 cells" refers to cells essentially completely depleted of mtDNA, and therefore have no functional mitochondrial respiration/ electron transport activity. Such absence of mitochondrial respiration may be established by demonstrating a lack of oxygen consumption by intact cells in the absence of glucose, and/or by demonstrating a lack of catalytic activity of electron transport chain enzyme complexes having subunits encoded by mtDNA, using methods well known in the art. (See, e.g., Miller et al., *J. Neurochem.* 67:1897-1907, 1996.) That cells have become ρ^0 cells may be further established by demonstrating that no mtDNA sequences are detectable within the cells. For example, using standard techniques well known to those familiar with the art, cellular mtDNA content may be measured using slot blot analysis of 1 μ g total cellular DNA probed with a mtDNA-specific oligonucleotide probe radiolabeled with, e.g., ^{32}P to a specific activity ≥ 900 Ci/gm. Under these conditions ρ^0 cells yield no detectable hybridizing probe signal. Alternatively, any other method known in the art for detecting the presence of mtDNA in a sample may be used that provides comparable sensitivity.

"Mitochondrial DNA depleted" cells ("mtDNA depleted cells") are cells substantially but not completely depleted of functional mitochondria and/or mitochondrial DNA, by any method useful for this purpose. MtDNA depleted cells are preferably at least about 80% depleted of mtDNA as measured using the slot blot assay described above for the determination of the presence of ρ^0 cells, and more preferably at

least about 90% depleted of mtDNA. Most preferably, mtDNA depleted cells are depleted of greater than about 95% of their mtDNA, wherein "about" indicates $\pm 5\%$ in each instance.

It is further known in the art to repopulate p^0 cells with mitochondria
5 derived from foreign cells in order to assess the contribution of the donor mitochondrial genotype to the respiratory phenotype of the recipient cells. Such cytoplasmic hybrid cells, containing genomic and mitochondrial DNAs of differing biological origins, are known as cybrids. Mitochondria to be transferred to construct cybrids or other model
10 systems in accordance with the present invention may be isolated from virtually any normal or diseased tissue or cell source, including subjects or biological sources known to have or be at risk for having a disease associated with altered mitochondrial function and subjects or biological sources known to be free of such a disease. Cell cultures of all types may potentially be used, as may cells from any tissue. However, fibroblasts, brain tissue, myoblasts and platelets are preferred sources of donor mitochondria.
15 Platelets are the most preferred, in part because of their ready abundance, and their lack of nuclear DNA. This preference is not meant to constitute a limitation on the range of cell types that may be used as donor sources.

For example, platelets may be isolated by an adaptation of the method of Chomyn (*Am. J. Hum. Genet.* 54:966-974, 1994). However, it is not necessary that this
20 particular method be used; other methods are easily substituted by those skilled in the art. For instance, if nucleated cells are used, cell enucleation and isolation of mitochondria isolation can be performed as described by Chomyn et al., *Mol. Cell. Biol.* 11:2236-2244, 1991. Human tissue from a subject having or being at risk for having a disease associated with altered mitochondrial function, or from a subject known to be
25 free of a risk or presence of such a disease, may be the source of donor mitochondria. In certain embodiments of the invention, human tissue from a plurality of subjects known to be free of a risk or presence of a disease associated with altered mitochondrial function is used as the source of mitochondria to be transferred into p^0 cells or mtDNA depleted cells to produce cybrid cells.

After preparation of mitochondria by isolation of platelets or enucleation of donor cells, the mitochondria may be transplanted into ρ^0 cells or mtDNA depleted cells using any known technique for introducing an organelle into a recipient cell, including but not limited to polyethylene glycol (PEG) mediated cell membrane fusion, cell membrane permeabilization, cell-cytoplasm fusion, virus mediated membrane fusion, liposome mediated fusion, particle mediated cellular uptake, microinjection or other methods known in the art. For example by way of illustration and not limitation, mitochondria donor cells ($\sim 1 \times 10^7$) are suspended in calcium-free Dulbecco's modified Eagle (DME) medium and mixed with ρ^0 cells ($\sim 0.5 \times 10^6$) in a total volume of 2 ml for 5 minutes at room temperature. The cell mixture is pelleted by centrifugation and resuspended in 150 μ l PEG (PEG 1000, J.T. Baker, Inc., 50% w/v in DME). After 1.5 minutes, the cell suspension is diluted with normal ρ^0 cell medium containing pyruvate, uridine and glucose, and maintained in tissue culture plates. Medium is replenished daily, and after one week medium lacking pyruvate and uridine is used to inhibit growth of unfused ρ^0 cells. These or other methods known in the art may be employed to produce cytoplasmic hybrid, or "cybrid", cell lines. Such cybrids are used according to the present invention as biological samples containing mitochondria, as described herein.

As a non-limiting example, cybrid model systems may be useful for screening candidate agents for treatment of a disease associated with altered mitochondrial function, or for diagnosing a patient suspected of having or being at risk for a disease associated with altered mitochondrial function. According to this example, the patient's mitochondria are used to construct cybrid cells as described above. These cybrid cells may then be propagated *in vitro* and used to provide a biological sample for the determination of mitochondrial permeability, which can be compared to mitochondrial permeability in a control cybrid cell line constructed with mitochondria from a subject known to be free of disease, or in particularly preferred embodiments, from a plurality of such subjects, as described above. Where it is desirable to compare the influence upon mitochondrial permeability, including the influence upon spontaneous or artificially induced MPT, of mitochondria from different sources, both

cybrid cell lines may be constructed from the same ρ^0 cell line to provide a constant background environment. These and similar uses of model systems according to the invention for screening candidate agents for treatment of, or for determining the risk for or presence of a disease associated with, altered mitochondrial function will be appreciated by those familiar with the art and are within the scope and spirit of the invention.

In addition, although the present invention is directed primarily towards model systems for diseases in which the mitochondria have metabolic alterations, it is not so limited. Conceivably there are disorders wherein mitochondria contain structural or morphological defects or anomalies, and the model systems of the present invention are of value, for example, to find drugs that can address that particular aspect of the disease. Also, there are certain individuals that have or are suspected of having extraordinarily effective or efficient mitochondrial function, and the model systems of the present invention may be of value in studying such mitochondria. Moreover, it may be desirable to put known normal mitochondria into cell lines having disease characteristics, in order to evaluate the influence of mitochondrial alterations on pathogenesis. All of these and similar uses are within the scope of the present invention, and the use of the phrase "mitochondrial alteration" herein should not be construed to exclude such embodiments.

The present invention provides compositions and methods that are useful in pharmacogenomics, for the classification and/or stratification of a subject or a patient population, for instance correlation of one or more traits in a subject with indicators of the responsiveness to, or efficacy of, a particular therapeutic treatment. In one aspect of the invention, measurement of mitochondrial permeability in a biological sample from a subject is combined with identification of the subject's apolipoprotein E (APOE) genotype to determine the risk for, or presence of, Alzheimer's disease (AD) in the subject. The apolipoprotein E type 4 allele (*APOE-ε4*) allele is a genetic susceptibility factor for sporadic AD and confers a two fold risk for AD (Corder et al., *Science* 261:921, 1993; see also "National Institute on Aging/Alzheimer's Association Working Group Consensus Statement," *Lancet* 347:1091, 1996.). Accordingly, in a preferred

embodiment of the invention, the method for determining the risk for or presence of AD in a subject by comparing mitochondrial permeability values will further comprise determining the APOE genotype of the subject suspected of being at risk for AD. By using the combination of the methods for determining mitochondrial permeability as disclosed herein, and methods known in the art for determining APOE genotype, an enhanced ability to detect the relative risk for AD is provided by the instant invention along with other related advantages. Similarly, where APOE genotype and risk for AD are correlated, the present invention provides advantageous methods for identifying agents suitable for treating AD where such agents affect mitochondrial permeability in a biological source.

As described herein, determination of mitochondrial permeability may be used to stratify an AD patient population. Accordingly, in another preferred embodiment of the invention, determination of mitochondrial permeability in a biological sample from an AD subject may provide a useful correlative indicator for that subject. An AD subject so classified on the basis of mitochondrial permeability may then be monitored using AD clinical parameters referred to above, such that correlation between mitochondrial permeability and any particular clinical score used to evaluate AD may be monitored. For example, stratification of an AD patient population according to mitochondrial permeability may provide a useful marker with which to correlate the efficacy of any candidate therapeutic agent being used in AD subjects. In a further preferred embodiment of this aspect of the invention, determination of mitochondrial permeability in concert with determination of an AD subject's APOE genotype may also be useful. These and related advantages will be appreciated by those familiar with the art.

The suitability of a compound (including, for example, a mitochondria protecting agent) for treatment of a subject having a disease associated with altered mitochondrial function may be determined by various assay methods. Such compounds are active in one or more of the following assays for measuring mitochondrial permeability transition, or in any other assay known in the art that directly or indirectly measures induction of MPT, MPT itself or any downstream sequelae of MPT, or that

may be useful for identifying mitochondrial permeability pore components (*i.e.*, molecules that regulate MPT). Accordingly, it is also an aspect of the invention to provide compositions and methods for treating a disease associated with altered mitochondrial function by administering a composition that regulates MPT. In
5 preferred embodiments of the invention, identification of agents to be formulated into such compositions may be according to the following assay methods.

A. Assay for Mitochondrial Permeability Transition (MPT) Using 2-,4-Dimethylaminostyryl-N-Methylpyridinium (DASPMI)

According to this assay, one may determine the ability of an agent
10 identified according to the present invention, for example, a mitochondria protecting agent, to inhibit the loss of mitochondrial membrane potential that accompanies mitochondrial dysfunction. As noted above, maintenance of a mitochondrial membrane potential ($\Delta\Psi_m$) may be compromised as a consequence of mitochondrial dysfunction. This loss of membrane potential, or mitochondrial permeability transition (MPT), can
15 be quantitatively measured using the mitochondria-selective fluorescent probe 2-,4-dimethylaminostyryl-N-methylpyridinium (DASPMI).

Upon introduction into cell cultures, DASPMI accumulates in mitochondria in a manner that is dependent on, and proportional to, mitochondrial membrane potential. If mitochondrial function is disrupted in such a manner as to
20 compromise membrane potential, the fluorescent indicator compound leaks out of the membrane bounded organelle with a concomitant loss of detectable fluorescence. Fluorimetric measurement of the rate of decay of mitochondria associated DASPMI fluorescence provides a quantitative measure of loss of membrane potential, or MPT. Because mitochondrial dysfunction may be the result of multiple factors that directly or
25 indirectly induce MPT as described above (*e.g.*, ROS, calcium flux), agents that retard the rate of loss of DASPMI fluorescence may be effective agents for treating diseases associated with altered mitochondrial function, according to the methods of the instant invention.

B. Assay of Apoptosis in Cells Treated with Mitochondria Protecting Agents

As noted above, mitochondrial dysfunction may be an induction signal for cellular apoptosis. According to this assay, one may determine the ability of a candidate agent (such as a candidate mitochondria protecting agent) to inhibit or delay the onset of apoptosis. Mitochondrial dysfunction may be present in cells known or suspected of being derived from a subject having a disease associated with altered mitochondrial function, or mitochondrial dysfunction may be induced in normal cells by one or more of a variety of physiological and biochemical stimuli, with which those having skill in the art will be familiar.

In one aspect of the apoptosis assay, cells that are suspected of undergoing apoptosis may be examined for morphological, permeability or other changes that are indicative of an apoptotic state. For example by way of illustration and not limitation, apoptosis in many cell types may cause altered morphological appearance such as plasma membrane blebbing, cell shape change, loss of substrate adhesion properties or other morphological changes that can be readily detected by those skilled in the art using light microscopy. As another example, cells undergoing apoptosis may exhibit fragmentation and disintegration of chromosomes, which may be apparent by microscopy and/or through the use of DNA specific or chromatin specific dyes that are known in the art, including fluorescent dyes. Such cells may also exhibit altered plasma membrane permeability properties as may be readily detected through the use of vital dyes (e.g., propidium iodide, trypan blue) or by the detection of lactate dehydrogenase leakage into the extracellular milieu. These and other means for detecting apoptotic cells by morphologic criteria, altered plasma membrane permeability and related changes will be apparent to those familiar with the art.

In another aspect of an apoptosis assay, translocation of cell membrane phosphatidylserine (PS) from the inner to the outer leaflet of the plasma membrane is detected by measuring outer leaflet binding by the PS-specific protein annexin. (Martin et al., *J. Exp. Med.* 182:1545, 1995; Fadok et al., *J. Immunol.* 148:2207, 1992.) In another aspect of the apoptosis assay, induction of specific protease activity in a family of apoptosis-activated proteases known as the caspases is measured, for example by determination of caspase-mediated cleavage of specifically recognized protein

substrates. These substrates may include, for example, poly-(ADP-ribose) polymerase (PARP) or other naturally occurring or synthetic peptides and proteins cleaved by caspases that are known in the art (*see, e.g.,* Ellerby et al., 1997 *J. Neurosci.* 17:6165). The synthetic peptide Z-Tyr-Val-Ala-Asp-AFC (SEQ ID NO:1; Example 6), wherein
5 "Z" indicates a benzoyl carbonyl moiety and AFC indicates 7-amino-4-trifluoromethylcoumarin (Kluck et al., 1997 *Science* 275:1132; Nicholson et al., 1995 *Nature* 376:37), is one such substrate. Other substrates include nuclear proteins such as U1-70 kDa and DNA-PKcs (Rosen and Casciola-Rosen, 1997 *J. Cell. Biochem.* 64:50; Cohen, 1997 *Biochem. J.* 326:1).

10 As described above, the mitochondrial inner membrane may exhibit highly selective and regulated permeability for many small molecules, including certain cations, but is impermeable to large (>~10 kDa) molecules. (*See, e.g.,* Quinn, 1976 *The Molecular Biology of Cell Membranes*, University Park Press, Baltimore, Maryland). Thus, in another aspect of the apoptosis assay, detection of the mitochondrial protein
15 cytochrome c that has leaked out of mitochondria in apoptotic cells may provide an apoptosis indicator that can be readily determined. (Liu et al., *Cell* 86:147, 1996) Such detection of cytochrome c may be performed spectrophotometrically, immunochemically or by other well established methods for determining the presence of a specific protein.

20 Release of cytochrome c from cells challenged with apoptotic stimuli (*e.g.,* ionomycin, a well known calcium ionophore) can be followed by a variety of immunological methods. Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry coupled with affinity capture is particularly suitable for such analysis since apo-cytochrome c and holo-cytochrome c can be distinguished
25 on the basis of their unique molecular weights. For example, the Surface-Enhanced Laser Desorption/Ionization (SELDI™) system (Ciphergen, Palo Alto, California) may be utilized to follow the inhibition by mitochondria protecting agents of cytochrome c release from mitochondria in ionomycin treated cells. In this approach, a cytochrome c specific antibody immobilized on a solid support is used to capture released cytochrome
30 c present in a soluble cell extract. The captured protein is then encased in a matrix of an

energy absorption molecule (EAM) and is desorbed from the solid support surface using pulsed laser excitation. The molecular mass of the protein is determined by its time of flight to the detector of the SELDI™ mass spectrometer.

The person of ordinary skill in the art will readily appreciate that there
5 may be other suitable techniques for quantifying apoptosis, and such techniques for purposes of determining the effects of mitochondria protecting agents on the induction and kinetics of apoptosis are within the scope of the assays disclosed here.

C. Assay of Electron Transport Chain (ETC) Activity in Isolated Mitochondria

As described above, mitochondria associated diseases may be
10 characterized by impaired mitochondrial respiratory activity that may be the direct or indirect consequence of elevated levels of reactive free radicals such as ROS, of elevated cytosolic free calcium concentrations or other stimuli. Accordingly, a suitable agent for use in the treatment of a disease associated with altered mitochondrial function may restore or prevent further deterioration of ETC activity in mitochondria of
15 individuals having mitochondria associated diseases. Assay methods for monitoring the enzymatic activities of mitochondrial ETC Complexes I, II, III, IV and ATP synthetase, and for monitoring oxygen consumption by mitochondria, are well known in the art. (See, e.g., Parker et al., *Neurology* 44:1090-96, 1994; Miller et al., *J. Neurochem.* 67:1897, 1996.) It is within the scope of the methods provided by the instant invention
20 to identify a suitable agent using such assays of mitochondrial function, given the relationship between mitochondrial membrane potential and ETC activity as described above. Further, mitochondrial function may be monitored by measuring the oxidation state of mitochondrial cytochrome c at 540 nm. Also as described above, oxidative damage that may arise in mitochondria associated diseases may include damage to
25 mitochondrial components such that the oxidation state of cytochrome c, by itself or in concert with other parameters of mitochondrial function including but not limited to mitochondrial oxygen consumption, may be an indicator of reactive free radical damage to mitochondrial components. Accordingly, the invention provides various assays designed to test the inhibition of such oxidative damage by candidate agents that may
30 influence mitochondrial membrane permeability. The various forms such assays may

take will be appreciated by those familiar with the art, and are not intended to be limited by the disclosures herein, including in the Examples.

For example by way of illustration and not limitation, Complex IV activity may be determined using commercially available cytochrome c that is fully
5 reduced via exposure to excess ascorbate. Cytochrome c oxidation may then be monitored spectrophotometrically at 540 nm using a stirred cuvette in which the ambient oxygen above the buffer is replaced with argon. Oxygen reduction in the cuvette may be concurrently monitored using a micro oxygen electrode with which those skilled in the art will be familiar, where such an electrode may be inserted into the
10 cuvette in a manner that preserves the argon atmosphere of the sample, for example through a sealed rubber stopper. The reaction may be initiated by addition of a cell homogenate or, preferably a preparation of isolated mitochondria, via injection through the rubber stopper. In the assay described here, for example, a defect in complex IV activity may be correlated with an enzyme recognition site. This assay, or others based
15 on similar principles, may permit correlation of mitochondrial respiratory activity with mitochondria membrane permeability, which may be determined according to other assays described herein.

Another embodiment of the invention involves its use identifying agents that increase the degree or enhance the rate of apoptosis in hyperproliferative cells
20 present in diseases and disorders such as cancer and psoriasis (note that, for the purposes of the disclosure, the term "hyperproliferative disease or disorder" specifically excludes pregnancy). Because oncogenic changes render certain tumors more susceptible to apoptosis (Evan and Littlewood, 1998 *Science* 281:1317), such agents are expected to be useful for treating such hyperproliferative diseases or disorders. In a
25 related embodiment, a biological sample from a patient having or suspected of having a hyperproliferative disease or disorder are evaluated for their susceptibility to such agents using the methods of the invention. Cybrid cells are a preferred biological sample in this embodiment.

A further embodiment of the invention involves its use in identifying
30 agents that alter mitochondrial function and/or selectively affect MPT in mitochondria

and/or cell death in a species-specific manner. By "species-specific manner" it is meant that such agents affect MPT or cell death in a first organism belonging to one species but not in a second organism belonging to another species. This embodiment of the invention is used in a variety of methods.

5 For example, this embodiment of the invention to identify agents that selectively induce MPT and/or apoptosis in biological samples comprising cells or mitochondria derived from different species, *e.g.*, in trypanosomes (Ashkenazi and Dixit, 1998 *Science* 281:1305), and other eukaryotic pathogens and parasites, including but not limited to insects, but which do not induce MPT and/or apoptosis in their
10 mammalian hosts. Such agents are expected to be useful for the prophylactic or therapeutic management of such pathogens and parasites.

 As another example, this embodiment of the invention is used to identify agents that selectively induce MPT and/or apoptosis in biological samples comprising cells or mitochondria derived from undesirable plants (*e.g.*, weeds) but not in desirable
15 plants (*e.g.*, crops), or in undesirable insects (in particular, members of the family *Lepidoptera* and other crop-damaging insects) but not in desirable insects (*e.g.*, bees) or desirable plants. Such agents are expected to be useful for the management and control of such undesirable plants and insects. Cultured insect cells, including for example, the Sf9 and Sf21 cell lines derived from *Spodoptera frugiperda*, and the HIGH FIVE™ cell
20 line from *Trichoplusia ni* (these three cell lines are available from InVitrogen, Carlsbad, California) may be biological sample in certain such embodiments of the invention.

 The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

EXAMPLE 1

ASSAY FOR MITOCHONDRIAL PERMEABILITY TRANSITION USING DASPMI

The fluorescent mitochondria-selective dye 2-,4-dimethylaminostyryl-N-methylpyridinium (DASPMI, Molecular Probes, Inc., Eugene, OR) is dissolved in
5 Hank's balanced salt solution (HBSS; Life Technologies, Rockville, MD) at 1mM and diluted to 25 μ M in warm HBSS. In 96-well microculture plates, monolayers of cultured human cytoplasmic hybrid (cybrid) cells produced by fusing mitochondrial DNA depleted (ρ^0) SH-SY5Y cells and mitochondria source platelets (Miller et al.,
10 1996 *J. Neurochem.* 67:1897-1907) from an individual known or suspected of having a disease associated with altered mitochondrial function, or from a pool ("MixCon") of platelets provided by several (typically three) normal donors known to be free of disease ("mixed control"), or unmodified SH-SY5Y parental neuroblastoma cells (Biedler et al., 1973 *Cancer Res.* 33:2643; Biedler et al., 1978 *Cancer Res.* 38:3751) at or near
15 confluence (*i.e.*, ~120,000 cells/well), are incubated for 0.5-1.5 hrs in 25 μ M DASPMI in a humidified 37 C/5% CO₂ incubator to permit mitochondrial uptake of the fluorescent dye. Culture supernatants are then removed and various concentrations of candidate agents diluted into HBSS from DMF stocks, or vehicle controls, are added. Candidate agents that may affect mitochondria permeability transition (MPT) are
20 introduced to cells from about 5 to about 20 minutes before the exposing the cells to ionomycin (described below), wherein "about" indicates \pm 10%.

Fluorescence of each microculture in the 96-well plate is quantified immediately using a Molecular Devices *fmax* fluorimetric plate reader (Molecular Devices Corp., Sunnyvale, California; excitation wavelength = 485 nm; emission
25 wavelength = 590 nm) and zero-time (t_0) fluorescence is recorded. Thereafter, induction of mitochondrial membrane potential collapse is initiated by the addition of ionomycin (Calbiochem, San Diego, California). Ionomycin stock solutions of various concentrations from 0.1-40 μ M are prepared in warm Hank's balanced salt solution (HBSS) and diluted for addition to cells to achieve a final concentration of 0.05-20 μ M,

with final concentrations of 4-10 μ M being preferred. Fluorescence decay of DASPMI-loaded, ionomycin induced cells is monitored as a function of time from 0-500 seconds following addition of ionomycin. The maximum negative slope (V-max) is calculated from a subset of the data using analysis software provided by the
5 fluorimetric plate reader manufacturer. In addition, the initial and final signal intensities are determined and the effects of candidate agents that may affect MPT on the rate of signal decay are quantified.

The fluorescence photomicrograph in Figure 1A shows mitochondrial labeling in mixed control SH-SY5Y neuroblastoma cybrid cells after being exposed to
10 75 μ M DASPMI for one hour in culture, as described above. MPT was then induced in these cells by contacting them with 1 μ M ionomycin. Figure 1B illustrates the collapse of mitochondrial membrane potential and concomitant loss of mitochondria-associated DASPMI fluorescence ten minutes after exposure to ionomycin.

EXAMPLE 2

15 INHIBITION OF IONOMYCIN INDUCED MPT BY CYCLOSPORIN USING THE DASPMI ASSAY

The method described in Example 1 was employed to monitor MPT induced by the calcium ionophore ionomycin and inhibition thereof by cyclosporin. Three cybrid cell lines were produced by fusing ρ^0 SH-SY5Y neuroblastoma cells with
20 pooled control platelets from cognitively normal, age-matched control donors or platelets from either of two patients diagnosed as having Alzheimer's disease (AD), as described above. Mitochondrial membrane potential-dependent labeling of mitochondria with DASPMI, fluorimetric detection of DASPMI and induction of MPT with ionomycin (5 μ M) were as described in Example 1. Cultures of each cybrid cell
25 line were incubated in unmodified media or in media containing 10 μ M cyclosporin (CalBiochem-Novabiochem Corp., San Diego, California) diluted from a 22 mM stock solution in DMSO for 10 minutes prior to MPT induction with ionomycin. Fluorescence detection and monitoring of fluorescence decay as a rate loss function were as described in Example 1.

As shown in Figure 2, DASPMI fluorescence loss rate as an indicator of mitochondrial membrane potential is significantly greater ($p < 0.0001$, as determined by ANOVA (Analysis Of Variance) using MICROSOFT™ Excel) in the two AD cybrid cell lines compared to the control cybrid cell line. As also shown in Figure 2, treatment
5 of a given cybrid cell line with cyclosporin prior to induction of MPT significantly retards the DASPMI fluorescence loss rate.

EXAMPLE 3

INHIBITION OF IONOMYCIN INDUCED MPT BY RUTHENIUM RED USING THE DASPMI ASSAY

10 Two cybrid cell lines were produced by fusing ρ^0 SH-SY5Y neuroblastoma cells with pooled control platelets from cognitively normal, age-matched control donors or platelets from a patient diagnosed as having Alzheimer's disease (AD), as described above. Mitochondrial membrane potential-dependent labeling of mitochondria with DASPMI, fluorimetric detection of DASPMI and induction of MPT
15 with ionomycin ($5 \mu\text{M}$) were as described in Example 1. Cultures of each cybrid cell line were incubated in unmodified media or in media containing 10 nM ruthenium red (Sigma Chemical Co., St. Louis, MO) diluted from a 1 mM stock for 10 minutes prior to MPT induction with ionomycin. Fluorescence detection and monitoring of fluorescence decay as a rate loss function were as described in Example 1.

20 As shown in Figure 3, DASPMI fluorescence loss rate as an indicator of mitochondrial membrane potential is significantly greater in cybrid cells that have not been treated with ruthenium red than in the cybrid cells that were pretreated with ruthenium red, which inhibits mitochondrial uptake of cytosolic free calcium (Masuoka et al., 1990 *Biochem. Biophys. Res. Commun.* 169:315).

EXAMPLE 4

ATRACTYLOSIDE INDUCED MPT USING THE DASPMI ASSAY IS ACCELERATED
IN AD CYBRIDS RELATIVE TO CONTROL CYBRIDS

Two cybrid cell lines were produced by fusing ρ^0 SH-SY5Y
5 neuroblastoma cells either with pooled control platelets from cognitively normal, age-
matched control donors or with platelets from a patient diagnosed as having
Alzheimer's disease (AD), as described above. Mitochondrial membrane potential-
dependent labeling of mitochondria with DASPMI, fluorimetric detection of DASPMI
and induction of MPT were as described in Example 1, except that MPT induction was
10 with 2.5 mM atractyloside (CalBiochem-Novabiochem Corp., San Diego, California) in
HBSS instead of with ionomycin. Cultures of the parental SH-SY5Y cell line and each
cybrid cell line were monitored beginning immediately upon MPT induction with
atractyloside. Fluorescence detection and monitoring of fluorescence decay as a rate
loss function were as described in Example 1.

15 As shown in Figure 4, following induction of MPT with atractyloside the
DASPMI fluorescence loss rate as an indicator of mitochondrial membrane potential is
significantly ($p < 0.01$) greater in the AD cybrid cell lines than in the control cybrid cell
line or the parental cell line.

EXAMPLE 5

20 ATRACTYLOSIDE INDUCED APOPTOSIS USING THE ANNEXIN ASSAY
FOR CELL SURFACE PHOSPHATIDYLSERINE IS ACCELERATED
IN AD CYBRIDS RELATIVE TO CONTROL CYBRIDS

Preparation of parental SH-SY5Y cells, control cybrid cells and AD
cybrid cells and induction of MPT using atractyloside were as described in Example 4.
25 Cells that became apoptotic following MPT were detected by binding of a detectably
labeled annexin V derivative (annexin-FITC) to cell surfaces as follows.

Exteriorization of plasma membrane phosphatidylserine (PS) was
assessed by adding to the 96 well plate annexin-fluorescein isothiocyanate conjugate

(annexin-FITC, Oncogene Research Products, Cambridge, MA) dissolved in a suitable buffer for binding to cell surfaces at a final concentration of 5 μ g/well, according to the manufacturer's recommendations. (Martin et al., *J. Exp. Med.* 182:1545, 1995) After 15-30 min in a humidified 37° C/ 5% CO₂ incubator, cells were fixed *in situ* using 2% formalin, washed to remove non-specifically bound FITC and read using a Cytofluor fluorimetric plate reader (model #2350, Millipore Corp., Bedford, Massachusetts; excitation wavelength = 485 nm; emission wavelength = 530 nm) to quantify cell surface bound annexin-FITC as a measure of outer leaflet PS, a marker for cells undergoing apoptosis.

10 As shown in Figure 5, following atractyloside induced MPT a significantly ($p < 0.01$) greater proportion of cell surface PS is detectable on AD cybrid cells relative to either control cybrid or parental SH-SY5Y cells, indicative of increased apoptosis in the AD cybrid cell population undergoing MPT.

EXAMPLE 6

15 INDUCTION OF MPT INDUCES APOPTOSIS

In 96-well microculture plates, cultured human cybrid neuroblastoma SH-SY5Y cells constructed using mitochondria from an individual known to have AD, or from a normal control subject, were cultured in HBSS followed by the addition of atractyloside (as described in Example 5) or ionomycin (as described in Example 1). Control cultures, to which neither atractyloside nor ionomycin were added, were prepared in parallel. Membrane potential was monitored from about 15 minutes (which was, in most cases, sufficient for purposes of the assay) to about 45 to 60 minutes, wherein "about" indicates $\pm 10\%$.

Caspase-3 activity was assessed by diluting the fluorogenic peptide substrate acetyl-Asp-Glu-Val-Asp (SEQ ID NO:2) conjugated to AMC (7-amino-4-methylcoumarin; the synthetic peptide is referred to as DEVD-AMC; CalBiochem-Novabiochem Corp., San Diego, California; see Walker et al., 1994 *Cell* 78:343, and Thornberry et al., 1992 *Nature* 356:768) from a DMSO stock solution into culture media to a final concentration of 20 μ M for uptake by cells. Substrate cleavage

liberating the AMC fluorophore was measured continuously using a Cytofluor fluorimetric plate reader (model #2350, Millipore Corp., Bedford, Massachusetts; excitation wavelength = 435 nm; emission wavelength = 460 nm). Data are presented as Δ RFU (relative fluorescence units). Caspase-1 activity (not shown) was measured
5 using the same protocol as that just described for caspase-3, except the caspase-1 specific fluorogenic substrate Z-Tyr-Val-Ala-Asp-AFC (SEQ ID NO:1; Example 6), wherein "Z" indicates a benzoyl carbonyl moiety and AFC indicates 7-amino-4-trifluoromethylcoumarin (CalBiochem-Novabiochem Corp., San Diego, California) is substituted for DEVD-AMC and fluorimetry is conducted using 405nm excitation and
10 510 nm emission. Caspase 3 is generally regarded as a mitochondrial-specific caspase, whereas caspase 1 is not; accordingly, DEVD-AMC is one preferred substrate for this embodiment of the invention.

Figure 6 shows caspase-3 activation, an indicator of apoptosis, following atractyloside induced MPT in control and AD cybrid cells. Significantly ($p < 0.05$,
15 ANOVA as described *supra*) increased and sustained apoptosis is apparent in cybrid cells constructed with mitochondria from an AD patient, relative to control cybrid cells.

Figure 7 shows caspase-3 activation following eight hours of ionomycin induced MPT in control and AD cybrid cells. Significantly ($p < 0.05$) increased and sustained apoptosis is apparent in cybrid cells constructed with mitochondria from an
20 AD patient, relative to control cybrid cells.

EXAMPLE 7

INDUCTION OF MPT WITH IONOMYCIN INDUCES APOPTOSIS DETECTABLE BY RELEASE OF CYTOCHROME C FROM MITOCHONDRIA

Control cybrid cells (MixCon) produced by fusing ρ^0 SH-SY5Y
25 neuroblastoma cells with pooled mitochondria source platelets from (typically three) normal subjects, and an AD cybrid cell line produced by fusing ρ^0 SH-SY5Y cells with mitochondria source platelets from an Alzheimer's Disease patient (Miller et al., 1996 *J. Neurochem.* 67:1897-1907), were grown to complete confluency in 6-well plates ($\sim 3 \times 10^6$ cells/ well). Cells were first rinsed with one volume 1X PBS, and then treated

with 10 μ M ionomycin in DMEM supplemented with 10% FCS, for 1 minute. Cells were then rinsed twice with five volumes of cold 1X PBS containing a cocktail of protease inhibitors (2 μ g/ml pepstatin, leupeptin, aprotinin, and 0.1 mM PMSF), and then collected in one ml of cold cytosolic extraction buffer (210 mM mannitol, 70 mM
5 mannitol, 5 mM each of HEPES, EGTA, glutamate and malate, 1 mM $MgCl_2$, and the protease inhibitor cocktail at the concentrations given above). Homogenization was carried out using 25 strokes with a type B dounce homogenizer on ice. Homogenates were centrifuged at maximum speed (14,000 x g) in an Eppendorf (Madison, Wisconsin) microfuge for five minutes to separate cytosol from intact cells, as well as
10 cell membranes and organelles. The supernatant was collected and an aliquot was saved, along with the pellet, at -80°C for citrate synthase and protein assays.

Cytochrome c antibody was covalently bound to solid support chips containing a pre-activated surface (PROTEINCHIP™, CIPHERGEN, Palo Alto, California). The surface area to be treated with antibody was initially hydrated with 1
15 μ l of 50% CH_3CN , and the antibody solution was added before the CH_3CN evaporated. The concentration of the antibody was approximately 1 mg/ml in either Na_3PO_4 or PBS buffer (pH 8.0). The chip was placed in a humid chamber and stored at 4°C overnight. Prior to addition of the cytosolic extract, residual active sites were blocked by treatment with 1.5 M ethanolamine (pH 8.0) for thirty minutes. The ethanolamine solution was
20 removed and the entire chip was washed in a 15 ml conical tube with 10 ml 0.05% Triton-X 100 in 1X PBS, for 5 minutes with gentle shaking at room temperature. The wash buffer was removed and the chip was sequentially washed, first with 10 ml 0.5 M NaCl in 0.1 M NaOAc (pH 4.5), and then with 0.5 M NaCl in 0.1M Tris (pH 8.0). After removal of the Tris-saline buffer, the chip was rinsed with 1X PBS and was ready
25 for capture of the antigen.

Fresh supernatant samples were spotted onto the CIPHERGEN ProteinChip containing covalently-linked anti-cytochrome c antibody (Pharmingen, San Diego, California). For optimal antibody-cytochrome c interaction, 100 μ l of the supernatant was used and the incubation was carried out overnight with shaking at 4°C in a
30 CIPHERGEN bioprocessing unit. The supernatant was then removed and the spots on the

chip were washed in the bioprocessing unit three times with 200 μ l of 0.1% Triton-X 100 in 1X PBS, and then twice with 200 μ l of 3.0 M urea in 1X PBS. The chips were then removed from the bioprocessor and washed with approximately 10 ml of dH₂O. The chips were then dried at room temperature prior to the addition of EAM solution
5 (e.g., sinapinic acid, CIPHERGEN, Palo Alto, California). A suspension of the EAM was made at a concentration of 25 mg/ml in 50% CH₃CN/H₂O containing 0.5% TFA. The saturated EAM solution was clarified by centrifugation and the supernatant was used for spotting on the ProteinChip surface. Prior to the addition of EAM to the chip, an internal standard of ubiquitin was added to the EAM solution to provide a final
10 concentration of 1 pmol / μ l. The quantification of cytochrome c released from mitochondria upon ionomycin treatment was based on normalization to the ubiquitin peak in the mass spectrum and the protein content of the cytosolic extracts. Citrate synthase activity of cytosolic extracts was measured to rule out the possibility of mitochondrial lysis during the sample preparation procedure.

15 Representative data depicting cytochrome c release in cells undergoing ionomycin induced apoptosis are presented in Figure 8. As shown in Figure 8, significantly ($p < 0.01$, ANOVA as described *supra*) greater quantities of cytochrome c were released from the mitochondria of AD cybrids undergoing ionomycin induced MPT than were released by the mitochondria of control cybrid cells.

20 EXAMPLE 8

IDENTIFICATION OF AN AGENT THAT REGULATES MPT BY MONITORING DASPMI LOSS RATE FOLLOWING IONOMYCIN INDUCED MPT

The assay for MPT by monitoring DASPMI fluorescence loss rate following induction of MPT was performed using two different AD cybrid cell lines
25 and a control cybrid cell line as described in Example 1, with the following exceptions: Some groups of cultured cybrid cells were exposed to 2 mM 1-phenylbiguanide (compound "I", RBI, Natick, Massachusetts) diluted in buffer or medium or to a vehicle control, for 20 min prior to MPT induction with 1 μ M ionomycin. As shown in Figure 9, 1-phenylbiguanide significantly ($p < 0.001$, ANOVA as described *supra*)

decreased the rate of loss of mitochondrial membrane potential following ionomycin induced MPT in all three cybrid cell lines.

EXAMPLE 9

IDENTIFICATION OF AGENT THAT REGULATES APOPTOSIS BY MONITORING CASPASE-3

5

ACTIVATION FOLLOWING IONOMYCIN INDUCED MPT

Control SH-SY5Y cells, and control (normal) and AD cybrids produced from SH-SY5Y cells were as described above, and were induced to undergo MPT as described in Example 1. Some cultured cells were pretreated with 1-phenylbiguanide (I) as described in Example 8. Briefly, SH-SY5Y neuroblastoma cells (1×10^5 cells) were rinsed with one volume 1X PBS, and then treated with 10 μ M ionomycin (Calbiochem, San Diego, California) in DMEM supplemented with 10% fetal calf serum (FCS) (Gibco, Life Technologies, Grand Island, New York) for 10 minutes, followed by two washes with DMEM (10% FCS). After 6h incubation at 37°C in DMEM with 10% FCS, cells were visualized by light microscopy (200X magnification) to detect characteristic changes in cellular morphology associated with apoptotic cells.

The results using parental SH-SY5Y cells are illustrated in Figure 10. The normal appearance of these cells prior to induction of MPT is shown in Figure 10A. After exposure to 10 μ M ionomycin for four hours, approximately 80% of ionomycin treated cells exhibited membrane blebbing (Figure 10B), indicative of entry by those cells into a final stage of apoptosis, compared to negligible apoptosis morphology (<5%) in untreated cells (not shown). Cells that were pretreated with (I) also exhibited substantially reduced apoptosis morphology (about 10-15% of cells; Figure 10C).

The effect of (I) on induction of the apoptosis-associated caspase-3 activity following ionomycin induced MPT was also assessed; as shown by its effect on DASPMI loss rate in Example 8, this agent inhibits MPT. Cells (AD cybrids or MixCon cybrids), cell culture, MPT induction and determination of caspase-3 activity were as described in Example 6, except that MPT was induced by 25 μ M ionomycin and indicated cultures were pretreated with (I) as described in Example 8. The results, shown in Figure 11 demonstrate that MPT induction by ionomycin induces significant

caspase-3 activity in these cells, and that this induction of caspase-3 activity is inhibited in cells pretreated with the MPT inhibitor 1-phenylbiguanide.

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration,
5 various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

We claim:

1. A method of identifying an agent that affects cell death comprising:
 - (a) contacting a first biological sample from a biological source with a candidate agent, wherein said first biological sample contains mitochondria;
 - (b) inducing cell death in said first biological sample and in a second biological sample from said biological source, wherein said second biological sample contains mitochondria;
 - (c) monitoring mitochondrial permeability transition in each of said first and second biological samples; and
 - (d) comparing mitochondrial permeability transition in said first biological sample to mitochondrial permeability transition in said second biological sample to detect a difference in mitochondrial permeability transition in said first biological sample relative to mitochondrial permeability transition in said second biological sample, and therefrom identifying an agent that affects cell death.
2. The method of claim 1 wherein said cell death is apoptosis.
3. The method of claim 1 wherein said cell death is necrosis.
4. The method of claim 1 wherein said first biological sample and said second biological sample are from a biological source having or suspected of being at risk for having a disease associated with altered mitochondrial function.
5. The method of claim 4 wherein said disease is selected from the group consisting of Alzheimer's Disease; diabetes mellitus; Parkinson's Disease; Huntington's disease; dystonia; Leber's hereditary optic neuropathy; schizophrenia; mitochondrial encephalopathy, lactic acidosis, and stroke (MELAS); cancer; psoriasis; hyperproliferative

disorders; mitochondrial diabetes and deafness (MIDD) and myoclonic epilepsy ragged red fiber syndrome.

6. The method of claim 1 wherein step (b) comprises contacting said first biological sample and said second biological sample with a compound that increases Ca^{2+} concentrations in said mitochondria.

7. The method of claim 1 wherein step (b) comprises contacting said first biological sample and said second biological sample with a compound that binds a mitochondrial component.

8. The method of either claim 6 or claim 7 wherein said compound is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

9. The method of either claim 6 or claim 7 wherein said compound binds a mitochondrial component and is selected from the group consisting of atractyloside and bongkreikic acid.

10. The method of claim 1 wherein step (b) comprises contacting said first biological sample and said second biological sample with a first compound that increases mitochondrial Ca^{2+} concentration and a second compound that binds a mitochondrial component.

11. The method of claim 1 wherein step (c) comprises contacting said samples with a detectable compound that accumulates in functioning mitochondria and that provides a detectable signal proportional to mitochondrial membrane potential.

12. The method of claim 11 wherein the detectable compound is selected from the group consisting of tetraphenylphosphonium ion; 2,4-dimethylaminostyryl-N-methyl pyridinium; tetramethylrhodamine methyl ester; tetramethylrhodamine ethyl ester; rhodamine 123; 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbezimidazolcarbocyanine iodide (JC-1); rhodamine 800; DiOC₆(3), rhodamine B hexyl ester and rhod-2.

13. A method of inhibiting apoptosis comprising contacting cells with 1-phenylbiguanide prior to or during said apoptosis.

14. A pharmaceutical composition comprising 1-phenylbiguanide.

15. The pharmaceutical composition of claim 14, further comprising a suitable carrier.

16. A method of identifying an agent that regulates mitochondrial permeability transition comprising:

a) contacting a first biological sample from a biological source with a candidate agent, wherein said first biological sample is a biological sample containing mitochondria;

b) inducing mitochondrial permeability transition in said first biological sample and in a second biological sample from said biological source, wherein said second biological sample is a biological sample containing mitochondria;

c) measuring mitochondrial membrane permeability in each of said first and second biological samples; and

d) comparing the amount of mitochondrial membrane permeability in the first biological sample to the amount of mitochondrial membrane permeability in the second biological sample to detect an effect of the candidate agent on mitochondrial membrane permeability, and therefrom determining suitability of the agent for treatment of a patient having a disease associated with altered mitochondrial function.

17. A method of identifying an agent suitable for treatment of a disease associated with altered mitochondrial function, comprising:

- a) identifying a candidate agent that binds to a mitochondrial molecular component;
- b) contacting a first biological sample containing mitochondria from a biological source with said candidate agent, wherein said first biological sample is a biological sample containing mitochondria;
- c) inducing mitochondrial permeability transition in said first biological sample and in a second biological sample containing mitochondria from said biological source, wherein said second biological sample is a biological sample containing mitochondria;
- d) measuring mitochondrial membrane permeability in each of said first and second biological samples; and
- e) comparing the amount of mitochondrial membrane permeability in the first biological sample to the amount of mitochondrial membrane permeability in the second biological sample to detect an effect of the candidate agent on mitochondrial membrane permeability, and therefrom determining suitability of the agent for treatment of a patient having a disease associated with altered mitochondrial function.

18. The method of claim 17 wherein the mitochondrial molecular component is selected from the group consisting of an adenine nucleotide translocator, an electron transport chain component, a voltage dependent anion channel protein, a mitochondrial calcium uniporter, a mitochondrial associated hexokinase, a peripheral benzodiazepine receptor, a mitochondrial intermembrane creatine kinase, cyclophilin D and a Bcl-2 gene family encoded polypeptide.

19. The method of either claim 16 or claim 17 wherein the biological source is a cybrid cell.

20. The method of either claim 16 or claim 17 wherein mitochondrial permeability transition is induced by atractyloside.

21. The method of either claim 16 or claim 17 wherein mitochondrial permeability transition is induced by bongkreikic acid.

22. The method of either claim 16 or claim 17 wherein the disease associated with altered mitochondrial function is selected from the group consisting of Alzheimer's Disease; diabetes mellitus; Parkinson's Disease; Huntington's disease; dystonia; Leber's hereditary optic neuropathy; schizophrenia; mitochondrial encephalopathy, lactic acidosis, and stroke (MELAS); cancer; psoriasis; hyperproliferative disorders; mitochondrial diabetes and deafness (MIDD) and myoclonic epilepsy ragged red fiber syndrome.

23. The method of either claim 16 or claim 17 wherein the disease associated with altered mitochondrial function is Alzheimer's Disease.

24. The method of either claim 16 or claim 17 wherein said first biological sample and said second biological sample are from a biological source having or suspected of being at risk for having a disease associated with altered mitochondrial function.

25. The method of either claim 16 or claim 17 wherein the step of inducing mitochondrial permeability transition comprises contacting said first biological sample and said second biological sample with a compound that increases Ca^{2+} concentrations in said mitochondria.

26. The method of claim 25 wherein said compound is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

27. The method of either claim 16 or claim 17 wherein the step of inducing mitochondrial permeability transition comprises contacting said first biological sample and said second biological sample with a compound that binds a mitochondrial component.

28. The method of claim 27 wherein said compound is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

29. The method of either claim 16 or claim 17 wherein the step of inducing mitochondrial permeability transition comprises contacting said first and second biological samples with an apoptogen.

30. The method of either claim 16 or claim 17 wherein the step of inducing mitochondrial permeability transition comprises contacting each of said first biological sample and said second biological sample with a first compound that increases mitochondrial Ca^{2+} concentration and with a second compound that binds a mitochondrial component.

31. The method of claim 30 wherein each of said first and second compounds is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

32. The method of either claim 16 or claim 17 wherein the step of measuring mitochondrial permeability comprises detecting an indicator of inner mitochondrial membrane potential.

33. The method of claim 32 wherein the indicator of inner mitochondrial membrane potential is selected from the group consisting of tetraphenylphosphonium ion; 2-,4-dimethylaminostyryl-N-methyl pyridinium; tetramethylrhodamine methyl ester;

tetramethylrhodamine ethyl ester; rhodamine 123; 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1); rhodamine 800; DiOC₆(3), rhodamine B hexyl ester and rhod-2.

34. The method of either claim 16 or claim 17 wherein the step of measuring mitochondrial permeability transition comprises detecting apoptosis.

35. The method of claim 34 wherein detecting apoptosis is selected from the group consisting of detecting altered cellular morphology, detecting DNA fragmentation, detecting translocation of phosphatidylserine to a plasma membrane outer leaflet, detecting induction of one or more caspase activities and detecting the release of cytochrome c from said mitochondria.

36. A method of inhibiting mitochondrial permeability transition in cells comprising contacting said cells with 1-phenylbiguanide prior to or during said mitochondrial permeability transition.

37. A method of identifying an agent that affects electron transport chain activity in mitochondria comprising:

(a) contacting a first sample from a biological source with a candidate agent, wherein said first sample contains mitochondria;

(b) inducing mitochondrial permeability transition in said first biological sample and in a second biological sample from said biological source, wherein said second sample contains mitochondria;

(c) monitoring mitochondrial permeability transition in each of said first and second samples; and

(d) comparing mitochondrial permeability transition in said first biological sample to mitochondrial permeability transition in said second biological sample to detect a difference in mitochondrial permeability transition in said first biological sample relative to

mitochondrial permeability transition in said second biological sample, and therefrom identifying an agent that affects electron transport chain activity.

38. A method of identifying an agent suitable for treatment of a patient having a disease associated with altered mitochondrial function, comprising:

- a) contacting a first biological sample from a biological source with a candidate agent, wherein said first biological sample is a biological sample containing mitochondria;
- b) inducing mitochondrial permeability transition in said first biological sample and in a second biological sample from said biological source, wherein said second biological sample is a biological sample containing mitochondria;
- c) measuring mitochondrial membrane permeability in each of said first and second biological samples; and
- d) comparing the amount of mitochondrial membrane permeability in the first biological sample to the amount of mitochondrial membrane permeability in the second biological sample to detect an effect of the candidate agent on mitochondrial membrane permeability, and therefrom determining suitability of the agent for treatment of a patient having a disease associated with altered mitochondrial function.

39. A method for detecting a risk or presence of a disease associated with altered mitochondrial function in a subject, comprising:

- a) inducing mitochondrial permeability transition in a first biological sample and in a second biological sample, wherein
said first biological sample contains mitochondria and is from a first subject suspected of having or being at risk for having a disease associated with altered mitochondrial function, and wherein
said second biological sample contains mitochondria and is from a second subject known to be free of a risk or presence of a disease associated with altered mitochondrial function;

b) measuring mitochondrial membrane permeability in each of said first and second biological samples; and

c) comparing the amount of mitochondrial membrane permeability in the first biological sample to the amount of mitochondrial membrane permeability in the second biological sample, and therefrom determining a risk or presence of a disease associated with altered mitochondrial function in said first subject.

40. The method of claim 39 wherein mitochondrial permeability transition in the first biological sample is induced in a cybrid cell having mitochondria from said first subject.

41. The method of claim 39 wherein mitochondrial permeability transition in the second biological sample is induced in a cybrid cell having mitochondria from said second subject.

42. The method of claim 41 wherein mitochondria from the second subject are derived from a plurality of subjects known to be free of a risk or presence of a disease associated with altered mitochondrial function.

43. The method of claim 39 wherein the step of inducing mitochondrial permeability transition comprises contacting said first biological sample and said second biological sample with a compound that increases Ca^{2+} concentrations in said mitochondria.

44. The method of claim 43 wherein said compound is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

45. The method of claim 39 wherein the step of inducing mitochondrial permeability transition comprises contacting said first biological sample and said second biological sample with a compound that binds a mitochondrial component.

46. The method of claim 45 wherein said compound is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

47. The method of claim 39 wherein the step of inducing mitochondrial permeability transition comprises contacting said first and second biological samples with an apoptogen.

48. The method of claim 39 wherein the step of inducing mitochondrial permeability transition comprises contacting each of said first biological sample and said second biological sample with a first compound that increases mitochondrial Ca^{2+} concentration and with a second compound that binds a mitochondrial component.

49. The method of claim 48 wherein each of said first and second compounds is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

50. The method of claim 39 wherein the step of measuring mitochondrial permeability comprises detecting an indicator of inner mitochondrial membrane potential.

51. The method of claim 50 wherein the indicator of inner mitochondrial membrane potential is selected from the group consisting of tetraphenylphosphonium ion; 2,4-dimethylaminostyryl-N-methyl pyridinium; tetramethylrhodamine methyl ester; tetramethylrhodamine ethyl ester; rhodamine 123; 5,5',6,6'-tetrachloro-1,1',3,3'-

tetraethylbezimidazolcarbocyanine iodide (JC-1); rhodamine 800; DiOC₆(3), rhodamine B hexyl ester and rhod-2.

52. The method of claim 39 wherein the step of measuring mitochondrial permeability transition comprises detecting apoptosis.

53. The method of claim 52 wherein detecting apoptosis is selected from the group consisting of detecting altered cellular morphology, detecting DNA fragmentation, detecting translocation of phosphatidylserine to a plasma membrane outer leaflet, detecting induction of one or more caspase activities and detecting the release of cytochrome c from said mitochondria.

54. The method of claim 39 wherein the disease associated with altered mitochondrial function is selected from the group consisting of Alzheimer's Disease; diabetes mellitus; Parkinson's Disease; Huntington's disease; dystonia; Leber's hereditary optic neuropathy; schizophrenia; mitochondrial encephalopathy, lactic acidosis, and stroke (MELAS); cancer; psoriasis; hyperproliferative disorders; mitochondrial diabetes and deafness (MIDD) and myoclonic epilepsy ragged red fiber syndrome.

55. The method of claim 39 wherein the disease associated with altered mitochondrial function is Alzheimer's Disease.

56. A method for identifying a mitochondrial molecular component that regulates mitochondrial permeability transition, comprising:

a) identifying a candidate agent that alters mitochondrial membrane permeability by

(i) contacting a first biological sample from a biological source with said candidate agent, wherein said first biological sample is a biological sample containing mitochondria;

(ii) inducing mitochondrial permeability transition in said first biological sample and in a second biological sample from said biological source, wherein said second biological sample is a biological sample containing mitochondria;

(iii) measuring mitochondrial membrane permeability in each of said first and second biological samples; and

(iv) comparing the amount of mitochondrial membrane permeability in the first biological sample to the amount of mitochondrial membrane permeability in the second biological sample to determine an effect of the candidate agent on mitochondrial membrane permeability; and

b) contacting the candidate agent with a plurality of mitochondrial molecular components under conditions and for a time sufficient to permit detectable binding of the candidate agent to at least one mitochondrial molecular component, and therefrom identifying a mitochondrial molecular component that regulates mitochondrial permeability transition.

57. The method of claim 56 wherein the biological source comprises a cybrid cell.

58. The method of claim 57 wherein the cybrid cell comprises mitochondria derived from a subject having a disease associated with altered mitochondrial function.

59. The method of claim 58 wherein the disease associated with altered mitochondrial function is selected from the group consisting of Alzheimer's Disease; diabetes mellitus; Parkinson's Disease; Huntington's Disease; dystonia; Leber's hereditary optic neuropathy; schizophrenia; mitochondrial encephalopathy, lactic acidosis, and stroke (MELAS); cancer; psoriasis; hyperproliferative disorders; mitochondrial diabetes and deafness (MIDD) and myoclonic epilepsy ragged red fiber syndrome.

60. The method of claim 58 wherein the disease associated with altered mitochondrial function is Alzheimer's Disease.

61. The method of claim 56 wherein the step of inducing mitochondrial permeability transition comprises contacting said first biological sample and said second biological sample with a compound that increases Ca^{2+} concentrations in said mitochondria.

62. The method of claim 61 wherein said compound is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

63. The method of claim 56 wherein the step of inducing mitochondrial permeability transition comprises contacting said first biological sample and said second biological sample with a compound that binds a mitochondrial component.

64. The method of claim 63 wherein said compound is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

65. The method of claim 56 wherein the step of inducing mitochondrial permeability transition comprises contacting said first and second biological samples with an apoptogen.

66. The method of claim 56 wherein the step of inducing mitochondrial permeability transition comprises contacting each of said first biological sample and said second biological sample with a first compound that increases mitochondrial Ca^{2+} concentration and with a second compound that binds a mitochondrial component.

67. The method of claim 66 wherein each of said first and second compounds is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

68. The method of claim 56 wherein the step of measuring mitochondrial permeability comprises detecting an indicator of inner mitochondrial membrane potential.

69. The method of claim 68 wherein the indicator of inner mitochondrial membrane potential is selected from the group consisting of tetraphenylphosphonium ion; 2-,4-dimethylaminostyryl-N-methyl pyridinium; tetramethylrhodamine methyl ester; tetramethylrhodamine ethyl ester; rhodamine 123; 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1); rhodamine 800; DiOC₆(3), rhodamine B hexyl ester and rhod-2.

70. The method of claim 56 wherein the step of measuring mitochondrial permeability transition comprises detecting apoptosis.

71. The method of claim 70 wherein detecting apoptosis is selected from the group consisting of detecting altered cellular morphology, detecting DNA fragmentation, detecting translocation of phosphatidylserine to a plasma membrane outer leaflet, detecting induction of one or more caspase activities and detecting the release of cytochrome c from said mitochondria.

72. The method of claim 59 wherein binding of the mitochondrial molecular component to the agent is determined by affinity isolation of the mitochondrial molecular component.

73. The method of claim 59 wherein binding of the mitochondrial molecular component to the agent is determined by affinity labeling of the mitochondrial molecular component.

74. The method of claim 59 wherein binding of the agent to the mitochondrial molecular component is determined following expression of a nucleic acid library encoding said mitochondrial molecular component.

75. A method for determining a risk for or presence of Alzheimer's disease in a subject, comprising:

- a) inducing mitochondrial permeability transition in a first biological sample from a first subject suspected of having or being at risk for having Alzheimer's disease and in a second biological sample from a second subject known to be free of having or being at risk for having Alzheimer's disease, wherein said first and second biological samples are biological samples containing mitochondria;
- b) measuring mitochondrial membrane permeability in each of said first and second biological samples;
- c) determining the apolipoprotein E genotype of each of said first and second subjects; and
- d) correlating the amount of mitochondrial membrane permeability in each of the first and second biological samples with the apolipoprotein E genotype of each of said first and second subjects, and therefrom determining a risk for or presence of Alzheimer's disease in the first subject.

76. The method of claim 75 wherein mitochondrial permeability transition in the first biological sample is induced in a cybrid cell having mitochondria from said first subject.

77. The method of claim 75 wherein mitochondrial permeability transition in the second biological sample is induced in a cybrid cell having mitochondria from said second subject.

78. The method of claim 77 wherein mitochondria from the second subject are derived from a plurality of subjects known to be free of having or being at risk for having Alzheimer's disease

79. The method of claim 75 wherein the step of inducing mitochondrial permeability transition comprises contacting said first biological sample and said second biological sample with a compound that increases Ca^{2+} concentrations in said mitochondria.

80. The method of claim 79 wherein said compound is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

81. The method of claim 75 wherein the step of inducing mitochondrial permeability transition comprises contacting said first biological sample and said second biological sample with a compound that binds a mitochondrial component.

82. The method of claim 81 wherein said compound is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

83. The method of claim 75 wherein the step of inducing mitochondrial permeability transition comprises contacting said first and second biological samples with an apoptogen.

84. The method of claim 75 wherein the step of inducing mitochondrial permeability transition comprises contacting each of said first biological sample and said second biological sample with a first compound that increases mitochondrial Ca^{2+} concentration and with a second compound that binds a mitochondrial component.

85. The method of claim 84 wherein each of said first and second compounds is selected from the group consisting of thapsigargin, an amino acid neurotransmitter, glutamate, N-methyl-D-aspartic acid, carbachol, an ionophore, ionomycin, an apoptogen, atractyloside and bongkreikic acid.

86. The method of claim 75 wherein the step of measuring mitochondrial permeability comprises detecting an indicator of inner mitochondrial membrane potential.

87. The method of claim 86 wherein the indicator of inner mitochondrial membrane potential is selected from the group consisting of tetraphenylphosphonium ion; 2-,4-dimethylaminostyryl-N-methyl pyridinium; tetramethylrhodamine methyl ester; tetramethylrhodamine ethyl ester; rhodamine 123; 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1); rhodamine 800; $\text{DiOC}_6(3)$, rhodamine B hexyl ester and rhod-2.

88. The method of claim 75 wherein the step of measuring mitochondrial permeability transition comprises detecting apoptosis.

89. The method of claim 88 wherein detecting apoptosis is selected from the group consisting of detecting altered cellular morphology, detecting DNA fragmentation, detecting translocation of phosphatidylserine to a plasma membrane outer leaflet, detecting induction of one or more caspase activities and detecting the release of cytochrome c from said mitochondria.

90. The method of any one of claims 34, 52, 70 or 88 wherein apoptosis is detected by measuring induction of a caspase protease activity that cleaves a polypeptide substrate.

91. The method of claim 90 wherein the caspase protease activity is selected from the group consisting of caspase-1 protease activity and caspase-3 protease activity.

92. The method of claim 91 wherein the caspase protease activity is caspase-1 protease activity.

93. The method of claim 91 wherein the caspase protease activity is caspase-3 protease activity.

94. The method of claim 91 wherein the polypeptide substrate is selected from the group consisting of Asp-Glu-Val-Asp-AMC and Tyr-Val-Ala-Asp-Z.

95. The method of any one of claims 34, 52, 70 or 88 wherein apoptosis is detected by determining the presence of cytochrome c released from mitochondria.

96. The method of claim 95, comprising determination of released cytochrome c by binding to an antibody specific for cytochrome c.

97. The method of claim 96, further comprising determining the molecular mass of released cytochrome c that binds to an antibody specific for cytochrome c by matrix assisted laser desorption ionization time-of-flight mass spectrometry.

98. A method of identifying an agent that regulates mitochondrial function in a species-specific manner comprising:

- (a) contacting a first biological sample with a candidate agent, wherein said first biological sample contains mitochondria and is from a biological source organism of a first species;
- (b) inducing mitochondrial permeability transition in said first sample and in a second biological sample, wherein said second sample contains mitochondria and is from an organism of a second species;
- (c) monitoring mitochondrial permeability transition in each of said first and second biological samples; and
- (d) comparing mitochondrial permeability transition in said first biological sample to mitochondrial permeability transition in said second biological sample to detect a difference in mitochondrial permeability transition in said first biological sample relative to mitochondrial permeability transition in said second biological sample, and therefrom identifying an agent that regulates mitochondrial function in a species specific manner.

99. The method of claim 98 wherein said first species is *Homo sapiens* and said second species is a eukaryotic pathogen or parasite of *Homo sapiens*.

100. An agent identified according to the method of claim 99.

101. The method of claim 98 wherein said first species is an undesired insect species and said second species is a desired insect species.

102. An agent identified according to the method of claim 101.

103. The method of claim 98 wherein said first species is an desired plant species and said second species is an undesired plant species or an undesired insect species.

104. The method of claim 103 wherein said undesired insect species is a member of the phylum *Lepidoptera*.

105. An agent identified according to the method of claim 104.

106. A method of identifying a genotype associated with a disease comprising:

(a) contacting a first biological sample from a biological source with a candidate agent, wherein said first biological sample contains mitochondria;

(b) inducing cell death in said first biological sample and in a second biological sample from said biological source, wherein said second biological sample contains mitochondria;

(c) monitoring mitochondrial permeability transition in each of said first and second biological samples; and

(d) comparing mitochondrial permeability transition in said first biological sample to mitochondrial permeability transition in said second biological sample to detect a difference in mitochondrial permeability transition in said first biological sample relative to mitochondrial permeability transition in said second biological sample, and therefrom identifying a genotype associated with the disease.

107. The method of claim 106 wherein said disease is selected from the group consisting of Alzheimer's disease, diabetes mellitus, Parkinson's disease, Huntington's disease, dystonia, Leber's hereditary optic neuropathy, mitochondrial encephalopathy, lactic acidosis, schizophrenia and myodegenerative disorders such as MELAS and MERRF.

108. A method of treating a disease associated with altered mitochondrial function, comprising administering a composition that regulates mitochondrial permeability transition.

Figure 1A



Figure 1B





Figure 2



Rate of DASPMI Loss (RFU/min)




Figure 3

Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10A



Figure 10B





Figure 10C



Figure 11



SEQUENCE LISTING

SEQ ID NO:1

Z = benzoyl carbonyl moiety

AFC = 7-amino-4-trifluoromethylcoumarin

Z-Tyr-Val-Ala-Asp-AFC

SEQ ID NO:2

AMC = 7-amino-4-methylcoumarin

Acetyl-Asp-Glu-Val-Asp-AMC

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/22261

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/50 G01N33/68 A61K31/00 C07C279/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H. FRIBERG ET AL.: " Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death" JOURNAL OF NEUROSCIENCE, vol. 18, no. 14, 15 July 1998 (1998-07-15), pages 5151-5159, XP002916359 abstract	108
A	--- -/--	1-107

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 January 2000

Date of mailing of the international search report

15/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Van Bohemen, C

INTERNATIONAL SEARCH REPORT

Int. Patent Application No
PCT/US 99/22261

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Medline. Washington DC USA; abstract no. 98214341, last sentence of abstract XP002128174 & T. HIRSCH ET AL.: " Mitochondrial permeability transition in apoptosis and necrosis " CELL BIOLOGY AND TOXICOLOGY, vol. 4, no. 2. 1 March 1998 (1998-03-01), pages 141-145. Amsterdam NL	1-108
Y		13, 14
X		14
Y	GB 1 410 925 A (J. DIAMOND ET AL.) 22 October 1975 (1975-10-22) examples 1-18	13, 14
X		14
A	BIOLOGICAL ABSTRACTS, Philadelphia PA USA, abstract no. PREV199800483471, abstract XP002128175 & M. BEAL ET AL.: " Mitochondrial dysfunction in neurodegenerative diseases " BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1366, no. 1-2, 10 August 1998 (1998-08-10), pages 211-223, Amsterdam NL	75-97

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 22261

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 108
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy. A search of claim 108 has been carried out, which was based on the alleged effects of the composition of said claim (cf. Rule 39.1(iv) and 67.1(iv) PCT).
2. ☒ Claims Nos.: 100, 102 & 105
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box 1.2

The present claims 100, 102 and 105 relate to a limitless number of possible agents. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the agents claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Also, the agents of claim 105 are characterized in functional terms. i.e. in terms of a result to be achieved, whereas in the present case, clarity ex Article 6 PCT could have been enhanced by defining said agents in concrete terms, e.g. by disclosing nomenclature or molecular structure. In consequence of the above, regarding claim 105, the search has been carried out based on the characterizing features of said agents as determined by claims 104, 103 and 98 to which independent claim 105 refers back; i.e. an agent that regulates mitochondrial permeability transition specifically in the species Lepidoptera. According to the same reasoning, regarding claim 102, the search was carried out for an agent that regulates mitochondrial permeability transition specifically in insect species and regarding claim 100 the search was carried out for an agent that regulates mitochondrial permeability transition specifically in pathogens of Homo sapiens. It could not be established whether any of the limitless number of agents disclosed in the prior art could have exhibited any of the above noted characteristics, if so tested.

The applicant's attention is drawn to the fact that claims, or parts of the claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 100, 102 & 105

The present claims 100, 102 and 105 relate to a limitless number of possible agents. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the agents claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Also, the agents of claim 105 are characterized in functional terms. i.e. in terms of a result to be achieved, whereas in the present case, clarity ex Article 6 PCT could have been enhanced by defining said agents in concrete terms, e.g. by disclosing nomenclature or molecular structure.

In consequence of the above, regarding claim 105, the search has been carried out based on the characterizing features of said agents as determined by claims 104, 103 and 98 to which independent claim 105 refers back; i.e. an agent that regulates mitochondrial permeability transition specifically in the species Lepidoptera. According to the same reasoning, regarding claim 102, the search was carried out for an agent that regulates mitochondrial permeability transition specifically in insect species and regarding claim 100 the search was carried out for an agent that regulates mitochondrial permeability transition specifically in pathogens of Homo sapiens. It could not be established whether any of the limitless number of agents disclosed in the prior art could have exhibited any of the above noted characteristics, if so tested.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 99/22261

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1410925 A	22-10-1975	NONE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)